2026/03/03 更新

写真a

カスガイ ダイスケ
春日井 大介
KASUGAI Daisuke
所属
医学部附属病院 救急科 病院助教
職名
病院助教

学位 2

  1. 博士(医学) ( 2023年7月   名古屋大学 ) 

  2. 学士(医学) ( 2015年3月   名古屋大学 ) 

研究キーワード 4

  1. オミクス解析

  2. 臓器障害

  3. 凝固障害

  4. 敗血症

研究分野 3

  1. ライフサイエンス / 救急医学  / 敗血症

  2. ライフサイエンス / 救急医学  / 急性肺障害とその後遺症

  3. ライフサイエンス / 救急医学  / sepsis mimics

経歴 3

  1. 藤田保健衛生大学   災害外傷外科   助手

    2018年4月 - 2019年3月

  2. 名古屋大学   医学部附属病院救急科   医員

    2017年4月 - 2018年3月

  3. 日本赤十字社医療センター

    2015年4月 - 2017年3月

学歴 2

  1. 名古屋大学   医学部   医学科

    2009年3月 - 2015年3月

  2. MPH iHOPE at the Johns Hopkins Bloomberg School of Public Health.

    2022年3月

所属学協会 2

  1. 日本救急医学会

    2017年4月 - 現在

  2. 日本集中治療医学会

    2017年4月 - 現在

委員歴 3

  1. 一般社団法人PHR普及推進協議会   PHR サービスガイドライン策定特別委員会 作業班  

    2023年   

  2. 日本集中治療医学会   Japanese Intensive Care Research Group (JICRG)・学会主導共同研究推進会議ワーキンググループ メンバー  

    2022年9月   

      詳細を見る

    団体区分:学協会

  3. 日本集中治療学会主導共同研究推進会議   ワーキンググループ  

    2022年   

      詳細を見る

    団体区分:学協会

受賞 2

  1. 最優秀演題賞

    2023年6月   日本集中治療医学会 第7回東海北陸支部学術集会  

     詳細を見る

    受賞区分:国内学会・会議・シンポジウム等の賞 

  2. Finalist Award

    2020年   SG HEALTHCARE AI DATATHON & EXPO  

 

論文 79

  1. The Impact of Hospital-Level Median Door-to-Extracorporeal Cardiopulmonary Resuscitation Time on the Prognosis of Patients With Refractory Out-of-Hospital Cardiac Arrest 査読有り 国際共著 国際誌 Open Access

    Kasugai, D; Okada, Y; Mizutani, Y; Honda, J; Kondo, T; Kazama, S; Yamamoto, T

    CRITICAL CARE MEDICINE   53 巻 ( 10 ) 頁: e2025 - e2032   2025年10月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Critical Care Medicine  

    OBJECTIVES: – To evaluate the impact of hospital-level median door-to-extracorporeal cardiopulmonary resuscitation (ECPR) time on survival and neurologic outcomes in patients with out-of-hospital cardiac arrest (OHCA) requiring ECPR. DESIGN: – Secondary analysis of the Japanese Association for Acute Medicine OHCA registry, a nationwide Japanese database of OHCA patients. SETTING: – Fifty-three hospitals across Japan. PATIENTS: – Adult patients who underwent ECPR between 2014 and 2021 were included. Hospitals were categorized into “rapid” or “delayed” groups based on their median door-to-ECPR times. INTERVENTIONS: – None. MEASUREMENTS AND MAIN RESULTS: – The primary outcome was 30-day survival. Secondary outcomes included 30-day and 90-day survival with favorable neurologic outcomes. Propensity score weighting was applied to adjust for confounders. In total, 2136 patients treated at 53 hospitals were included. Hospitals with shorter median door-to-ECPR times had higher 30-day survival rates (odds ratio [OR], 1.36; 95% CI, 1.21–1.53). Neurologic outcomes were better in the rapid hospital group at both 30 days (OR, 1.47; 95% CI, 1.24–1.73) and 90 days (OR, 1.47; 95% CI, 1.25–1.73) follow-ups. CONCLUSIONS: – Hospital-level median door-to-ECPR time is a crucial predictor of survival and neurologic outcomes in OHCA patients requiring ECPR. Shorter door-to-ECPR times should be considered a key quality metric for ECPR processes.

    DOI: 10.1097/CCM.0000000000006808

    Open Access

    Web of Science

    Scopus

    PubMed

  2. Association between Loss of Hypercoagulable Phenotype, Clinical Features and Complement Pathway Consumption in COVID-19 招待有り 査読有り

    Kasugai D, Tanaka T, Suzuki T, et al.

    Frontiers in Immunology     2024年3月

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)  

  3. Physical function and mental health trajectories in COVID-19 patients following invasive mechanical ventilation: a prospective observational study 査読有り 国際誌 Open Access

    Yamamoto Hiromasa, Tanaka Shinya, Kasugai Daisuke, Shimizu Miho, Tsuchikawa Yohei, Hori Yuto, Fugane Yuki, Inoue Takayuki, Nagaya Motoki, Omote Norihito, Higashi Michiko, Yamamoto Takanori, Jingushi Naruhiro, Numaguchi Atsushi, Goto Yukari, Nishida Yoshihiro

    SCIENTIFIC REPORTS   13 巻 ( 1 ) 頁: 14529   2023年9月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Scientific Reports  

    This prospective observational cohort study was performed to investigate the physical function and mental health trajectories of novel coronavirus disease 2019 (COVID-19) patients requiring invasive mechanical ventilation (IMV) after discharge from the intensive care unit (ICU). The study population consisted of 64 patients (median age, 60 years; 85.9% male; median IMV duration, 9 days). At ICU discharge, 28.1% of the patients had Medical Research Council (MRC) sum score < 48 points, and prolonged IMV was significantly associated with lower MRC sum score and handgrip strength. Symptoms were similar between groups at ICU discharge, and the symptoms most commonly reported as moderate-to-severe were impaired well-being (52%), anxiety (43%), tiredness (41%), and depression (35%). Although muscle strength and mobility status were significantly improved after ICU discharge, Edmonton Symptom Assessment System score did not improve significantly in the prolonged IMV group. EuroQol five-dimension five-level summary index was significantly lower in the prolonged than short IMV group at 6 months after ICU discharge. We found substantial negative physical function and mental health consequences in the majority of surviving COVID-19 patients requiring IMV, with prolonged period of IMV showing greater negative effects not only immediately but also at 6 months after discharge from the ICU.

    DOI: 10.1038/s41598-023-41684-3

    Open Access

    Web of Science

    Scopus

    PubMed

  4. Clinical implications of urine output-based sepsis-associated acute kidney injury 査読有り 国際誌

    Kasugai Daisuke, Nakashima Takaya, Goto Tadahiro

    INTENSIVE CARE MEDICINE   49 巻 ( 10 ) 頁: 1263 - 1265   2023年8月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Intensive Care Medicine  

    DOI: 10.1007/s00134-023-07190-w

    Web of Science

    Scopus

    PubMed

  5. Challenges hindering emergency physicians; involvement in multicenter collaborative studies in Japan: A nationwide survey analysis 査読有り 国際共著 国際誌 Open Access

    Yasuda, M; Saito, A; Goto, T; Yamamoto, R; Liu, KB; Kuriyama, A; Kondo, Y; Kasugai, D

    ACUTE MEDICINE & SURGERY   10 巻 ( 1 ) 頁: e906   2023年1月

     詳細を見る

    担当区分:最終著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/ams2.906

    Open Access

    Web of Science

    PubMed

  6. The Mystery of Futility of Appropriate Antibiotics for Coinfection in COVID-19 査読有り 国際誌 Open Access

    Kasugai Daisuke, Jingushi Naruhiro, Omote Norihiro, Shindo Yuichiro, Goto Yukari

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   204 巻 ( 12 ) 頁: 1489 - 1489   2021年12月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:American Journal of Respiratory and Critical Care Medicine  

    DOI: 10.1164/rccm.202107-1656LE

    Open Access

    Web of Science

    Scopus

    PubMed

  7. Clinical impact of visually assessed right ventricular dysfunction in patients with septic shock 査読有り 国際誌 Open Access

    Hiraiwa Hiroaki, Kasugai Daisuke, Ozaki Masayuki, Goto Yukari, Jingushi Naruhiro, Higashi Michiko, Nishida Kazuki, Kondo Toru, Furusawa Kenji, Morimoto Ryota, Okumura Takahiro, Matsuda Naoyuki, Matsui Shigeyuki, Murohara Toyoaki

    SCIENTIFIC REPORTS   11 巻 ( 1 ) 頁: 18823   2021年9月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Scientific Reports  

    We retrospectively analyzed data from the Medical Information Mart for Intensive Care-III critical care database to determine whether visually-assessed right ventricular (RV) dysfunction was associated with clinical outcomes in septic shock patients. Associations between visually-assessed RV dysfunction by echocardiography and in-hospital mortality, lethal arrhythmia, and hemodynamic indicators to determine the prognostic value of RV dysfunction in patients with septic shock were analyzed. Propensity score analysis showed RV dysfunction was associated with increased risk of in-hospital death in patients with septic shock (adjusted odds ratio [OR] 2.15; 95% confidence interval [CI] 1.99–2.32; P < 0.001). In multivariate logistic regression analysis, RV dysfunction was associated with in-hospital death (OR 2.19; 95% CI 1.91–2.53; P < 0.001), lethal arrhythmia (OR 2.19; 95% CI 1.34–3.57; P < 0.001), and tendency for increased blood lactate levels (OR 1.31; 95% CI 1.14–1.50; P < 0.001) independent of left ventricular (LV) dysfunction. RV dysfunction was associated with lower cardiac output, pulmonary artery pressure index, and RV stroke work index. In patients with septic shock, visually-assessed RV dysfunction was associated with in-hospital mortality, lethal arrhythmia, and circulatory insufficiency independent of LV dysfunction. Visual assessment of RV dysfunction using echocardiography might help to identify the short-term prognosis of patients with septic shock by reflecting hemodynamic status.

    DOI: 10.1038/s41598-021-98397-8

    Open Access

    Web of Science

    Scopus

    PubMed

  8. Relative platelet reductions provide better pathophysiologic signatures of coagulopathies in sepsis 査読有り 国際誌 Open Access

    Kasugai Daisuke, Ozaki Masayuki, Nishida Kazuki, Goto Yukari, Takahashi Kunihiko, Matsui Shigeyuki, Matsuda Naoyuki

    SCIENTIFIC REPORTS   11 巻 ( 1 ) 頁: 14033   2021年7月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Scientific Reports  

    In sepsis-associated coagulopathies and disseminated intravascular coagulation, relative platelet reductions may reflect coagulopathy severity. However, limited evidence supports their clinical significance and most sepsis-associated coagulopathy criteria focus on the absolute platelet counts. To estimate the impact of relative platelet reductions and absolute platelet counts on sepsis outcomes. A multicenter retrospective observational study was performed using the eICU Collaborative Research Database, comprising 335 intensive care units (ICUs) in the United States. Patients with sepsis and an ICU stay > 2 days were included. Estimated effects of relative platelet reductions and absolute platelet counts on mortality and coagulopathy-related complications were evaluated. Overall, 26,176 patients were included. Multivariate mixed-effect logistic regression analysis revealed marked in-hospital mortality risk with larger platelet reductions between days one and two, independent from the resultant absolute platelet counts. The adjusted odds ratio (OR) [95% confidence intervals (CI)] for in-hospital mortality was 1.28[1.23–1.32], 1.86[1.75–1.97], 2.99[2.66–3.36], and 6.05[4.40–8.31] for 20–40%, 40–60%, 60–80%, and > 80% reductions, respectively, when compared with a < 20% decrease in platelets (P < 0.001 for each). In the multivariate logistic regression analysis, platelet reductions ≥ 11% and platelet counts ≤ 100,000/μL on day 2 were associated with high coagulopathy-related complications (OR [95%CI], 2.03 and 1.18; P < 0.001 and P < 0.001), while only platelet reduction was associated with thromboembolic complications (OR [95%CI], 1.43 [1.03–1.98], P < 0.001). The magnitude of platelet reductions represent mortality risk and provides a better signature of coagulopathies in sepsis; therefore, it is a plausible criterion for sepsis-associated coagulopathies.

    DOI: 10.1038/s41598-021-93635-5

    Open Access

    Web of Science

    Scopus

    PubMed

  9. Timing of administration of epinephrine predicts the responsiveness to epinephrine in norepinephrine-refractory septic shock: a retrospective study 査読有り Open Access

    Kasugai Daisuke, Nishikimi Mitsuaki, Nishida Kazuki, Higashi Michiko, Yamamoto Takanori, Numaguchi Atsushi, Takahashi Kunihiko, Matsui Shigeyuki, Matsuda Naoyuki

    JOURNAL OF INTENSIVE CARE   7 巻 ( 1 ) 頁: 20   2019年4月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of Intensive Care  

    Background: Currently, the appropriate method of management of patients with refractory septic shock remains unclear. This study aimed to evaluate the factors associated with response to epinephrine in norepinephrine-refractory septic shock. Methods: A retrospective single-center observational study was performed using data from adult patients (≥ 18 years old) admitted to our emergency and medical intensive care unit (ICU) from January 2014 to December 2017 who had received epinephrine to treat norepinephrine-refractory septic shock. The response was considered positive if there was increase in mean arterial pressure of 10 mmHg or decrease in arterial lactate level 3 h after epinephrine administration. Results: Forty-one patients were included: 24 responders (59%) and 17 non-responders (41%). Responders showed higher rate of survival from shock (92% vs. 18%; P < 0.001), and 28-day survival (83% vs. 18%; P < 0.001). In multivariable analysis, time of epinephrine administration after ICU admission (odds ratio [OR] 0.48; 95% confidence interval [CI] 0.27-0.87; P = 0.011) and SOFA score (OR 0.19; 95% CI 0.04-0.88; P = 0.034) were associated with epinephrine response. Time of epinephrine administration was also significantly associated with survival from shock (OR 0.42; P = 0.005) and 28-day survival (OR 0.14; P = 0.006), while SOFA score did not. Using inverse probability of treatment weighing (IPTW) adjustment of propensity score, epinephrine administration later than 24 h after ICU admission was associated with poor response (OR 0.07; 95% CI 0.02-0.21; P < 0.001). Conclusions: Early administration of epinephrine after ICU admission (i.e., within 24 h) is associated with better hemodynamic status in patients with refractory septic shock.

    DOI: 10.1186/s40560-019-0377-1

    Open Access

    Web of Science

    Scopus

    PubMed

  10. scSurv: a deep generative model for single-cell survival analysis Open Access

    Mizukoshi, C; Kojima, Y; Hayashi, S; Abe, K; Kasugai, D; Shimamura, T

    BIOINFORMATICS   42 巻 ( 1 )   2026年1月

     詳細を見る

    記述言語:英語   出版者・発行元:Bioinformatics  

    Motivation Single-cell omics analysis has unveiled the heterogeneity of various cell types within tumors. However, no methodology currently reveals how this heterogeneity influences cancer patient survival at single-cell resolution. Here, we introduce scSurv, combining a Cox proportional hazards model with a deep generative model of single-cell transcriptome, to estimate individual cellular contributions to clinical outcomes. Results The accuracy of scSurv was validated using both simulated and real datasets. This method identifies cells associated with favorable or adverse prognoses and extracts genes correlated with their contribution levels. In melanoma, scSurv reproduces known prognostic macrophage classifications and facilitates hazard mapping through spatial transcriptomics in renal cell carcinoma. We also identified genes consistently associated with prognosis across multiple cancers and demonstrated the applicability of this method to infectious diseases. scSurv is a novel framework for quantifying the heterogeneity of individual cellular effects on clinical outcomes.

    DOI: 10.1093/bioinformatics/btaf671

    Open Access

    Web of Science

    Scopus

    PubMed

  11. Target for Anticoagulation in the Management of Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock Rationale and Design for a Pilot Randomized Controlled Trial Open Access

    Kazama, S; Kondo, T; Hiroaki, H; Morimoto, R; Okumura, T; Honda, J; Tanaka, T; Higashi, M; Yamamoto, T; Numaguchi, A; Kuwatsuka, Y; Ando, M; Yamaguchi, S; Uemura, Y; Sawamura, A; Watanabe, N; Morishima, I; Haga, T; Shinoda, M; Murohara, T; Kasugai, D

    CHEST CRITICAL CARE   3 巻 ( 4 )   2025年12月

     詳細を見る

    出版者・発行元:Chest Critical Care  

    Background: Bleeding and thromboembolic complications are significant challenges in the treatment of patients with cardiogenic shock (CS) who require venoarterial extracorporeal membrane oxygenation (VA-ECMO). Anticoagulation strategies that target higher activated partial thromboplastin time (aPTT) may exacerbate bleeding and lead to poor outcomes. However, there is a lack of sufficient randomized trials to determine the optimal aPTT target for this patient population. Research Question: Does anticoagulation management with a lower aPTT target range improve outcomes compared with a higher aPTT target range in patients with CS who are treated with VA-ECMO? Study Design and Methods: The Target for Anticoagulation in the Management of Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock (TARGET-ECMO) trial is a multicenter, randomized controlled trial designed to evaluate the impact of different aPTT target ranges on outcomes in patients with CS who are treated with VA-ECMO. Patients are randomized into 1 of 2 groups: a lower aPTT target group (aPTT, 1.5 to1.8 times) or a higher aPTT target group (aPTT, 2.2 to 2.5 times). Results: The primary end point is a hierarchic composite outcome assessed at 7 days that consists of (1) death from any cause, (2) major bleeding, (3) thromboembolic events, and (4) total transfusion of RBC concentrates, which are evaluated with the use of a win ratio. Interpretation: Anticoagulation targets in VA-ECMO management typically are determined at the discretion of individual centers and clinicians. The Target for Anticoagulation in the Management of Venoarterial Extracorporeal Membrane Oxygenation for CS trial aims to improve the prognosis of patients with CS who are treated with VA-ECMO by exploring optimal aPTT target range for anticoagulation management. Clinical Trial Registration: Certified Review Board of Nagoya University Hospital (approval number: 2024-0166) and the Japan Registry of Clinical Trials (jRCT1041240069).

    DOI: 10.1016/j.chstcc.2025.100198

    Open Access

    Web of Science

    Scopus

  12. Prediction Capability of Physical Assessment at Intensive Care Unit Discharge for Long-Term Functional Outcomes in Patients with Sepsis

    Watanabe, S; Morita, Y; Nakamura, K; Nakano, H; Motoki, M; Kamijo, H; Matsuoka, A; Ishii, K; Hongo, T; Shimojo, N; Tanaka, Y; Hanazawa, M; Hamagami, T; Oike, K; Kasugai, D; Sakuda, Y; Irie, Y; Nitta, M; Akieda, K; Shimakura, D; Ono, M; Katsukawa, H; Kotani, T; Ogura, T; Liu, KB

    JOURNAL OF INTENSIVE CARE MEDICINE     頁: 8850666251383483   2025年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Intensive Care Medicine  

    Background: Long-term physical dysfunction common among intensive care unit (ICU) survivors and mortality remains a concern even after hospital discharge. Although early identification of patients at risk for these outcomes is essential, few studies have investigated whether physical assessments at ICU discharge can predict physical dysfunction or death at 3, 6, and 12 months after discharge. The purpose of this study was to examine the association between physical assessment at ICU discharge and the incidence of physical functional disability or death within 12 months after discharge. Methods: This was a multicenter prospective cohort study of 21 ICUs in Japan. Patients with sepsis admitted to the ICU for >48 h were enrolled. The primary outcome was physical dysfunction (Barthel index ≤90) or death at 3, 6, and 12 months after discharge. Physical assessments at the time of ICU discharge included the Medical Research Council (MRC) score, handgrip strength, and the Barthel index. A multiple logistic regression model and area under the curve (AUC) were used. Results: In total, 300 ICU patients (median age, 74 years) were included. MRC score (odds ratio [OR]: 0.98, 95% confidence interval [CI]: 0.96-0.99, cut-off: 46), hand grip strength (OR: 0.95, 95%CI: 0.92-0.98, cut-off: 12.0 kg), and Barthel index (OR: 0.96, 95%CI 0.95-0.98, cut-off: 15) were independent predictors of physical dysfunction or death at 12 months after hospital discharge and at 3 and 6 months. The Barthel index at ICU discharge showed the highest AUC for physical function or death at 12 months (0.718). The Barthel index and hand grip strength were also associated with cognitive dysfunction or mental disorders. Conclusions: In ICU patients with sepsis, clinically available physical and muscle strength assessments at ICU discharge were significantly associated with physical dysfunction incidence or death over the first year of hospital discharge. Trial registration number: UMIN000041433

    DOI: 10.1177/08850666251383483

    Web of Science

    Scopus

    PubMed

  13. Japan Intensive Care Consortium: Nationwide Effort for Extracorporeal Membrane Oxygenation Care Optimization and Excellence Study: Study Protocol.

    Kasugai D, Yamamoto R, Kobayashi H, Owaki T, Kobayashi M, Honda J, Isomoto T, Okano H, Matsumoto T, Sunada T, Kawauchi A, Kajino T, Shiba M, Ohi T, Funahashi Y, Sato S, Tanaka S, Sato H, Hongo T, Kyo M, Yarimizu K, Morishita T, Endo T, Kanda T, Morishima I, Yokokawa Y, Suzuki T, Yoshino Y, Maezawa T, Nakamura T, Yamamoto T, ECMO NEXT study investigators

    Annals of clinical epidemiology   7 巻 ( 4 ) 頁: 128 - 136   2025年10月

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人 日本臨床疫学会  

    DOI: 10.37737/ace.25016

    PubMed

    CiNii Research

  14. Association of Medical Burden and Capacity Changes With Clinical Outcomes Among Patients Without COVID-19 During the Pandemic: A Multicenter Retrospective Cohort Study

    Sakuraya, M; Sugimoto, T; Kikutani, K; Takeda, C; Kasugai, D; Okano, H; Aoki, Y; Shimada, H; Kawakami, D; Hirata, A; Santanda, T; Nakane, M; Kumasawa, J; Fukushima, T; Ota, K; Moriyama, N; Uchida, M; Irie, H; Ishii, K; Mataichi, K; Shiotsuka, J; Sugimoto, K; Kobayashi, N; Kumashiro, R; Koyama, Y; Shime, N

    CRITICAL CARE MEDICINE   53 巻 ( 10 ) 頁: e1918 - e1929   2025年10月

     詳細を見る

    記述言語:英語   出版者・発行元:Critical Care Medicine  

    OBJECTIVES: – The spillover impact of the COVID-19 pandemic on patients without COVID-19 in ICUs should be assessed. We aimed to assess the association of ICUs’ medical burden and capacity changes with clinical outcomes in such patients during the COVID-19 pandemic. DESIGN: – Retrospective cohort study. SETTING: – Twenty-three ICUs in Japan. PATIENTS: – Patients without COVID-19 in ICUs from January 2019 to February 2023. INTERVENTIONS: – None. MEASUREMENTS AND MAIN RESULTS: – These ICUs completed a web-based questionnaire on medical burden and capacity limitations in November 2023, and they were classified as having a limited capacity if their scores exceeded the median; otherwise, they were categorized as having a maintained capacity. The primary outcome was the standardized mortality ratio (SMR), calculated with the Acute Physiology and Chronic Health Evaluation III-j model, compared with the pre-pandemic level. Using individual-level patient data, a generalized linear Poisson mixed-effects model including an offset-time term was employed to assess the association of capacity limitation, the number of patients with COVID-19, and ICU bed occupancy on the day of admission, with hazard ratios for in-hospital death. Nine and fourteen ICUs had a limited capacity (25, 568 patients) and a maintained capacity (45, 068 patients), respectively. SMRs increased in four epidemic waves in the ICUs with a limited capacity but in only one wave in those with a maintained capacity. After adjustment, capacity limitation (hazard ratio, 1.19; 95% CI, 1.01–1.41; p = 0.04) and the number of patients with severe COVID-19 (per five patients; hazard ratio, 1.09; 95% CI, 1.03–1.16; p = 0.002) were associated with in-hospital mortality, but ICU bed occupancy was not. CONCLUSIONS: – SMRs increased more frequently in ICUs with a limited capacity during the pandemic. Our findings emphasize the need for proactive strategies to mitigate medical burden and capacity limitations for future preparedness.

    DOI: 10.1097/CCM.0000000000006785

    Web of Science

    Scopus

    PubMed

  15. Nationwide survey of adherence to the Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024 in the initial management of sepsis Open Access

    Oami, T; Kasugai, D; Yamakawa, K; Matsuoka, T; Kano, K; Aoki, Y; Yatabe, T; Shime, N; Nakada, T

    JOURNAL OF INTENSIVE CARE   13 巻 ( 1 ) 頁: 51   2025年9月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Intensive Care  

    Background: The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2024 (J-SSCG2024) were developed to improve the standardization and quality of sepsis care across various clinical settings. However, real-world adherence to these recommendations among healthcare professionals in Japan remains unclear. The objective of this study was to assess patterns of adherence to the J-SSCG2024 and identify factors associated with variation in clinical practice. Methods: We conducted a nationwide web-based cross-sectional survey targeting healthcare professionals, administering a questionnaire that included 23 items reflecting the key J-SSCG2024 recommendations for the initial management of sepsis, along with demographic and professional background information. Cluster analysis was performed to identify the distinct adherence patterns. Subgroup analyses were conducted to explore the association between respondent characteristics and guideline compliance. Additionally, sensitivity analyses were performed to evaluate the robustness of the findings across distinct cluster numbers. Results: A total of 734 healthcare professionals participated in the survey, most of whom were physicians (92.4%) with over 20 years of clinical experience (54.0%). High adherence was observed for recommendations, such as blood purification and the use of first-line vasopressors. However, substantial variation was detected in practices related to adjuvant therapies and initial resuscitation, particularly regarding the timing of vasopressor initiation and the use of beta-blockers. Cluster analysis revealed four distinct adherence profiles. Higher adherence was associated with expertise in emergency and critical care medicine, affiliation with intensive care units or emergency departments, and a higher number of patients with sepsis managed monthly. These findings were consistent across the sensitivity analyses. Conclusions: This nationwide survey identified characteristic clusters based on adherence to the J-SSCG2024 among Japanese clinicians. Targeted implementation strategies are essential to enhance guideline adoption, particularly among clinicians outside specialized critical care settings.

    DOI: 10.1186/s40560-025-00819-6

    Open Access

    Web of Science

    Scopus

    PubMed

  16. Incidence of diffuse parenchymal lung disease in patients meeting the Berlin definition of acute respiratory distress syndrome on mechanical ventilation Open Access

    Norisue, Y; Yamamoto, R; Yamakawa, H; Hibino, M; Nagai, T; Fujimoto, Y; Kataoka, J; Ishii, K; Hongo, T; Kasugai, D; Iwasaki, Y; Sakuraya, M; Shimizu, G; Masuyama, T; Fujitani, S; Tokuda, Y; Ogura, T

    ERJ OPEN RESEARCH   11 巻 ( 5 )   2025年9月

     詳細を見る

    記述言語:英語   出版者・発行元:Erj Open Research  

    Background The simplicity of the diagnostic definition of acute respiratory distress syndrome (ARDS) has led to its diagnosis in patients with new-onset or exacerbation of diffuse parenchymal lung diseases (DPLDs). This study investigated the incidence of DPLDs in patients with acute hypoxic respiratory failure who met the Berlin definition. Methods This Japan-based multicentre retrospective cohort study included patients on mechanical ventilation who met the Berlin definition. For all participants, diagnosis was made by pulmonology specialists in DPLD and thoracic radiology (blinded to clinical diagnoses) by reviewing an extensive database designed for DPLD diagnosis across 10 participating hospitals. Results Of 13 612 patients admitted to the intensive care unit during the study period, 272 met the Berlin definition of ARDS and were included for analysis. All underwent at least one chest computed tomography scan; none underwent lung biopsy. Briefly, 182 were designated classic ARDS (67%), 69 non-IPF (idiopathic pulmonary fibrosis) DPLDs (25%) and 21 IPF (8%) by DPLD specialists. Of the 90 patients diagnosed with DPLD (IPF or non-IPF) by specialists, 35% were diagnosed with classic ARDS by intensivists at the end of the clinical course. Diagnostic classifications of classic ARDS and IPF by DPLD specialists were associated with time-to-death (adjusted hazard ratio (HR) 1.58 (95% CI 1.03–2.45), p=0.038, and adjusted HR 1.73 (95% CI 1.01–2.97), p=0.045, respectively) and in-hospital mortality (adjusted HR 1.54 (95% CI 1.06–2.23), p=0.022 for classic ARDS) versus non-IPF DPLDs; intensivist diagnostic classifications were not. Conclusion Approximately one-third of patients within the Berlin definition were retrospectively diagnosed with new-onset or acutely exacerbated DPLD by specialists.

    DOI: 10.1183/23120541.01296-2024

    Open Access

    Web of Science

    Scopus

    PubMed

  17. One-year outcomes in sepsis: a prospective multicenter cohort study in Japan (vol 13, 23, 2025) Open Access

    Liu, KB; Watanabe, S; Nakamura, K; Nakano, H; Motoki, M; Kamijo, H; Ayaka, M; Ishii, K; Morita, Y; Hongo, T; Shimojo, N; Tanaka, Y; Hanazawa, M; Hamagami, T; Oike, K; Kasugai, D; Sakuda, Y; Irie, Y; Nitta, M; Akieda, K; Shimakura, D; Katsukawa, H; Kotani, T; McWilliams, D; Nydahl, P; Schaller, SJ; Ogura, T

    JOURNAL OF INTENSIVE CARE   13 巻 ( 1 ) 頁: 28   2025年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Intensive Care  

    Following publication of the original article [1], a sentence in Abstract Result section has been corrected from: “The rate of death for those who met PICS Criteria at hospital discharge was 89%, with a death or PICS incidence of 73%, 64%, and 65% at 3, 6, and 12 months, respectively.” to: “The rate of death or those who met PICS Criteria at hospital discharge was 89%, with a death or PICS incidence of 73%, 64%, and 65% at 3, 6, and 12 months, respectively.” The original article [1] has been updated.

    DOI: 10.1186/s40560-025-00799-7

    Open Access

    Web of Science

    Scopus

    PubMed

  18. Global Burden of Mechanical Ventilation (GEMINI Study): An Epidemiological and Geoeconomic Modelling Study

    Penuelas, O; Muriel, A; Albendea, LD; Quoc, LC; Son, DN; Saldarriaga, FM; Siempos, II; Pinheiro, B; Arabi, Y; Garcia, PW; Juffermans, N; Laffey, J; Ming-Cheng, C; Cakar, N; Thille, A; Rios, F; Aguirre, H; Jibaja, M; Maggiore, S; Del Sorbo, L; Brochard, LJ; Nin, N; Romero, MM; Bin, D; Bugedo, G; Patel, B; Murali, M; Povoa, P; Nobile, L; Kasugai, D; Young, SG; Martinez, NR; Zeggwagh, A; Seeliger, B; Fortis, S; Dostal, P; Avila, A; Podbregar, M; Abroug, F; Myatra, SN; Fakher, MM; Sutherasan, Y; Anzueto, A; Esteban, A; Frutos-Vivar, F

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   211 巻   2025年5月

  19. One-year outcomes in sepsis: a prospective multicenter cohort study in Japan Open Access

    Liu, K; Watanabe, S; Nakamura, K; Nakano, H; Motoki, M; Kamijo, H; Ayaka, M; Ishii, K; Morita, Y; Hongo, T; Shimojo, N; Tanaka, Y; Hanazawa, M; Hamagami, T; Oike, K; Kasugai, D; Sakuda, Y; Irie, Y; Nitta, M; Akieda, K; Shimakura, D; Katsukawa, H; Kotani, T; Mcwilliams, D; Nydahl, P; Schaller, SJ; Ogura, T

    JOURNAL OF INTENSIVE CARE   13 巻 ( 1 ) 頁: 23   2025年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Intensive Care  

    Background: Sepsis is a leading cause of death in intensive care units (ICU). Sepsis survivors are often left with significant morbidity, termed post-intensive care syndrome (PICS), impacting post-sepsis life. The aim was to present detailed data on the prognostic and functional long-term outcomes of ICU patients with sepsis in Japan, which is currently lacking and therefore prevents development of targeted solutions. Methods: A multicenter prospective study, involving 21 ICUs in 20 tertiary hospitals in Japan, included all consecutive adult ICU patients between November 2020 and April 2022, and diagnosed with sepsis at ICU admission (Sepsis 3). Follow-ups were performed at 3, 6, and 12 months after hospital discharge by telephone and mail. Primary outcome was death or incidence of PICS, defined by any of physical dysfunction (Barthel Index ≤ 90), cognitive dysfunction (Short Memory Questionnaire < 40), or mental disorder (any subscales for anxiety or depression of Hospital Anxiety and Depression Scale ≥ 8, or Impact of Event Scale-Revised ≥ 25). Secondary outcomes included Quality of Life (QOL), employment, and use of hospital, emergency, rehabilitation, and psychiatric services. A multivariable analysis investigated independent factors associated with each dysfunction at each follow-up. Results: A total of 339 patients were included (median age 74 [67–82] years, 60% male, 77% septic shock, and a median SOFA of 9 [6–12]). Mortality was 23% at hospital discharge, increasing to 37% at 12 months. The rate of death for those who met PICS Criteria at hospital discharge was 89%, with a death or PICS incidence of 73%, 64%, and 65% at 3, 6, and 12 months, respectively. Limited improvements in QOL and return to work (44%), high rates of hospital readmissions (40%), frequent emergency service usage (31%), and low utilization of rehabilitation and psychiatric services (15% and 7%) were identified over the first year. The incidence of any PICS-related dysfunction was consistently an independent factor for the incidence of the same dysfunction at the following follow-ups. Conclusions: This multicenter study identified the distinct realities of post-sepsis life in Japanese ICU patients, highlighting the unique challenges in improving their functions and returning to daily life. Trial Registration University Hospital Medical Information Network UMIN000041433

    DOI: 10.1186/s40560-025-00792-0

    Open Access

    Web of Science

    Scopus

    PubMed

  20. Clinical features and treatments of VEXAS syndrome in critical care: a scoping review Open Access

    Satoh, K; Tsujimoto, Y; Kasugai, D; Okura, K; Luthe, SK; Ono, T; Miyamoto, Y; Matsuyama, T; Okuyama, M; Watase, T; Nakae, H; Goto, T

    CRITICAL CARE   29 巻 ( 1 ) 頁: 154   2025年4月

     詳細を見る

    記述言語:英語   出版者・発行元:Critical Care  

    Background: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a recently discovered severe disorder that predominantly affects adult males, characterized by systemic inflammation and hematologic abnormalities. Despite its profound impact on patient outcomes, awareness of VEXAS syndrome among critical care providers remains severely limited, often leading to delayed recognition, diagnosis, and initiation of appropriate treatment. This study aims to address this knowledge gap by conducting a scoping review on VEXAS syndrome in the critical care setting. Methods: This scoping review followed the PRISMA-ScR guidelines and Joanna Briggs Institute methodology, analyzing data from Cochrane CENTRAL, MEDLINE via PubMed, EMBASE, and Web of Science on May 19, 2024. We included studies that reported clinical features and treatments of patients with VEXAS syndrome requiring critical care. Results: Of the 1262 reports identified, 78 reports met the inclusion criteria, including 45 case reports/series, 17 observational studies, 15 reviews, and one systematic review. Analysis of 55 cases revealed a median age of 69 with a strong male predominance (54/55). ICU admission rates ranged from 28 to 33%, with mortality rates between 18 and 40%. Critical manifestations included shock, hemophagocytic lymphohistiocytosis, acute respiratory distress syndrome, thrombosis, and airway edema. Sepsis was the leading cause of death, followed by other causes including VEXAS syndrome related organ failure, cardiovascular events, and intestinal perforation. Treatment approaches combined conventional critical care measures with immunosuppressive and immunomodulatory therapies, although infectious complications were frequently reported. Conclusion: This review revealed the lack of systematically analyzed studies focusing on VEXAS syndrome in the critical care setting, suggesting a significant gap in understanding the clinical characteristics and optimal treatments for VEXAS syndrome. Further research focused on VEXAS syndrome in the critical care setting is essential to improve early recognition, develop standardized treatment protocols, and ultimately improve patient outcomes in this complex patient population.

    DOI: 10.1186/s13054-025-05390-y

    Open Access

    Web of Science

    Scopus

    PubMed

  21. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024 Open Access

    Shime, N; Nakada, T; Yatabe, T; Yamakawa, K; Aoki, Y; Inoue, S; Iba, T; Ogura, H; Kawai, Y; Kawaguchi, A; Kawasaki, T; Kondo, Y; Sakuraya, M; Taito, S; Doi, K; Hashimoto, H; Hara, Y; Fukuda, T; Matsushima, A; Egi, M; Kushimoto, S; Oami, T; Kikutani, K; Kotani, Y; Aikawa, G; Aoki, M; Akatsuka, M; Asai, H; Abe, T; Amemiya, Y; Ishizawa, R; Ishihara, T; Ishimaru, T; Itosu, Y; Inoue, H; Imahase, H; Imura, H; Iwasaki, N; Ushio, N; Uchida, M; Uchi, M; Umegaki, T; Umemura, Y; Endo, A; Oi, M; Ouchi, A; Osawa, I; Oshima, Y; Ota, K; Ohno, T; Okada, Y; Okano, H; Ogawa, Y; Kashiura, M; Kasugai, D; Kano, K; Kamidani, R; Kawauchi, A; Kawakami, S; Kawakami, D; Kawamura, Y; Kandori, K; Kishihara, Y; Kimura, S; Kubo, K; Kuribara, T; Koami, H; Koba, S; Sato, T; Sato, R; Sawada, Y; Shida, H; Shimada, T; Shimizu, M; Shimizu, K; Shiraishi, T; Shinkai, T; Tampo, A; Sugiura, G; Sugimoto, K; Sugimoto, H; Suhara, T; Sekino, M; Sonota, K; Taito, M; Takahashi, N; Takeshita, J; Takeda, C; Tatsuno, J; Tanaka, A; Tani, M; Tanikawa, A; Chen, H; Tsuchida, T; Tsutsumi, Y; Tsunemitsu, T; Deguchi, R; Tetsuhara, K; Terayama, T; Togami, Y; Totoki, T; Tomoda, Y; Nakao, S; Nagasawa, H; Nakatani, Y; Nakanishi, N; Nishioka, N; Nishikimi, M; Noguchi, S; Nonami, S; Nomura, O; Hashimoto, K; Hatakeyama, J; Hamai, Y; Hikone, M; Hisamune, R; Hirose, T; Fuke, R; Fujii, R; Fujie, N; Fujinaga, J; Fujinami, Y; Fujiwara, S; Funakoshi, H; Homma, K; Makino, Y; Matsuura, H; Matsuoka, A; Matsuoka, T; Matsumura, Y; Mizuno, A; Miyamoto, S; Miyoshi, Y; Murata, S; Murata, T; Yakushiji, H; Yasuo, S; Yamada, K; Yamada, H; Yamamoto, R; Yamamoto, R; Yumoto, T; Yoshida, Y; Yoshihiro, S; Yoshimura, S; Yoshimura, J; Yonekura, H; Wakabayashi, Y; Wada, T; Watanabe, S; Ijiri, A; Ugata, K; Uda, S; Onodera, R; Takahashi, M; Nakajima, S; Honda, J; Matsumoto, T

    JOURNAL OF INTENSIVE CARE   13 巻 ( 1 ) 頁: 15   2025年3月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Intensive Care  

    The 2024 revised edition of the Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock (J-SSCG 2024) is published by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine. This is the fourth revision since the first edition was published in 2012. The purpose of the guidelines is to assist healthcare providers in making appropriate decisions in the treatment of sepsis and septic shock, leading to improved patient outcomes. We aimed to create guidelines that are easy to understand and use for physicians who recognize sepsis and provide initial management, specialized physicians who take over the treatment, and multidisciplinary healthcare providers, including nurses, physical therapists, clinical engineers, and pharmacists. The J-SSCG 2024 covers the following nine areas: diagnosis of sepsis and source control, antimicrobial therapy, initial resuscitation, blood purification, disseminated intravascular coagulation, adjunctive therapy, post-intensive care syndrome, patient and family care, and pediatrics. In these areas, we extracted 78 important clinical issues. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) method was adopted for making recommendations, and the modified Delphi method was used to determine recommendations by voting from all committee members. As a result, 42 GRADE-based recommendations, 7 good practice statements, and 22 information-to-background questions were created as responses to clinical questions. We also described 12 future research questions.

    DOI: 10.1186/s40560-025-00776-0

    Open Access

    Web of Science

    Scopus

    PubMed

  22. Phenotypes of Functional Decline or Recovery in Sepsis ICU Survivors: Insights From a 1-Year Follow-Up Multicenter Cohort Analysis. 査読有り 国際共著 国際誌

    Liu K, Nakashima T, Goto T, Nakamura K, Nakano H, Motoki M, Kamijo H, Ayaka M, Ishii K, Morita Y, Hongo T, Shimojo N, Tanaka Y, Hanazawa M, Hamagami T, Oike K, Kasugai D, Sakuda Y, Irie Y, Nitta M, Akieda K, Shimakura D, Katsukawa H, Kotani T, Nydahl P, Schaller SJ, Ogura T, Investigating Long term Outcomes of ICU patients with Sepsis or Septic shock (ILOSS) Study Group

    Critical care medicine     2025年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/CCM.0000000000006621

    PubMed

  23. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024. 査読有り 国際誌 Open Access

    Shime N, Nakada TA, Yatabe T, Yamakawa K, Aoki Y, Inoue S, Iba T, Ogura H, Kawai Y, Kawaguchi A, Kawasaki T, Kondo Y, Sakuraya M, Taito S, Doi K, Hashimoto H, Hara Y, Fukuda T, Matsushima A, Egi M, Kushimoto S, Oami T, Kikutani K, Kotani Y, Aikawa G, Aoki M, Akatsuka M, Asai H, Abe T, Amemiya Y, Ishizawa R, Ishihara T, Ishimaru T, Itosu Y, Inoue H, Imahase H, Imura H, Iwasaki N, Ushio N, Uchida M, Uchi M, Umegaki T, Umemura Y, Endo A, Oi M, Ouchi A, Osawa I, Oshima Y, Ota K, Ohno T, Okada Y, Okano H, Ogawa Y, Kashiura M, Kasugai D, Kano KI, Kamidani R, Kawauchi A, Kawakami S, Kawakami D, Kawamura Y, Kandori K, Kishihara Y, Kimura S, Kubo K, Kuribara T, Koami H, Koba S, Sato T, Sato R, Sawada Y, Shida H, Shimada T, Shimizu M, Shimizu K, Shiraishi T, Shinkai T, Tampo A, Sugiura G, Sugimoto K, Sugimoto H, Suhara T, Sekino M, Sonota K, Taito M, Takahashi N, Takeshita J, Takeda C, Tatsuno J, Tanaka A, Tani M, Tanikawa A, Chen H, Tsuchida T, Tsutsumi Y, Tsunemitsu T, Deguchi R, Tetsuhara K, Terayama T, Togami Y, Totoki T, Tomoda Y, Nakao S, Nagasawa H, Nakatani Y, Nakanishi N, Nishioka N, Nishikimi M, Noguchi S, Nonami S, Nomura O, Hashimoto K, Hatakeyama J, Hamai Y, Hikone M, Hisamune R, Hirose T, Fuke R, Fujii R, Fujie N, Fujinaga J, Fujinami Y, Fujiwara S, Funakoshi H, Homma K, Makino Y, Matsuura H, Matsuoka A, Matsuoka T, Matsumura Y, Mizuno A, Miyamoto S, Miyoshi Y, Murata S, Murata T, Yakushiji H, Yasuo S, Yamada K, Yamada H, Yamamoto R, Yamamoto R, Yumoto T, Yoshida Y, Yoshihiro S, Yoshimura S, Yoshimura J, Yonekura H, Wakabayashi Y, Wada T, Watanabe S, Ijiri A, Ugata K, Uda S, Onodera R, Takahashi M, Nakajima S, Honda J, Matsumoto T

    Acute medicine & surgery   12 巻 ( 1 ) 頁: e70037   2025年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/ams2.70037

    Open Access

    PubMed

  24. 施設間ECMO広域三角搬送を経験して ─ 紹介元病院の立場から ─

    本多 純太, 田中 卓, 春日井 大介

    日本集中治療医学会雑誌   32 巻 ( 0 ) 頁: n/a   2025年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本集中治療医学会  

    DOI: 10.3918/jsicm.32_r16

    CiNii Research

  25. At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods Open Access

    Mesinovic M., Wong X.C., Rajahram G.S., Citarella B.W., Peariasamy K.M., van Someren Greve F., Olliaro P., Merson L., Clifton L., Kartsonaki C., Abdukahil S.A., Abdulkadir N.N., Abe R., Abel L., Abrous A., Absil L., Acker A., Adachi S., Adam E., Adriano E., Adrião D., Ageel S.A., Ahmed S., Aiello M., Ainscough K., Airlangga E., Aisa T., Hssain A.A., Tamlihat Y.A., Akimoto T., Akmal E., Qasim E.A., Alalqam R., Alberti A., Al-dabbous T., Alegesan S., Alegre C., Alessi M., Alex B., Alexandre K., Al-Fares A., Alfoudri H., Ali A., Ali I., Alidjnou K.E., Aliudin J., Alkhafajee Q., Allavena C., Allou N., Alves J., Alves R., Cabrita J.A., Amaral M., Amira N., Ammerlaan H., Ampaw P., Andini R., Andréjak C., Angheben A., Angoulvant F., Ansart S., Anthonidass S., Antonelli M., de Brito C.A.A., Anwar K.R., Apriyana A., Arabi Y., Aragao I., Arancibia F., Araujo C., Arcadipane A., Archambault P., Arenz L., Arlet J.B., Arnold-Day C., Arora L., Arora R., Artaud-Macari E., Aryal D., Asaki M., Asensio A., Ashley E.A., Ashraf M., Assie J.B., Asyraf A., Atique A., Attanyake A.U.L., Auchabie J., Aumaitre H., Auvet A., Azemar L., Azoulay C., Bach B., Bachelet D., Badr C., Baig N., Baillie J.K., Baird J.K., Bak E.

    Scientific Reports   14 巻 ( 1 )   2024年12月

     詳細を見る

    出版者・発行元:Scientific Reports  

    By September 2022, more than 600 million cases of SARS-CoV-2 infection have been reported globally, resulting in over 6.5 million deaths. COVID-19 mortality risk estimators are often, however, developed with small unrepresentative samples and with methodological limitations. It is highly important to develop predictive tools for pulmonary embolism (PE) in COVID-19 patients as one of the most severe preventable complications of COVID-19. Early recognition can help provide life-saving targeted anti-coagulation therapy right at admission. Using a dataset of more than 800,000 COVID-19 patients from an international cohort, we propose a cost-sensitive gradient-boosted machine learning model that predicts occurrence of PE and death at admission. Logistic regression, Cox proportional hazards models, and Shapley values were used to identify key predictors for PE and death. Our prediction model had a test AUROC of 75.9% and 74.2%, and sensitivities of 67.5% and 72.7% for PE and all-cause mortality respectively on a highly diverse and held-out test set. The PE prediction model was also evaluated on patients in UK and Spain separately with test results of 74.5% AUROC, 63.5% sensitivity and 78.9% AUROC, 95.7% sensitivity. Age, sex, region of admission, comorbidities (chronic cardiac and pulmonary disease, dementia, diabetes, hypertension, cancer, obesity, smoking), and symptoms (any, confusion, chest pain, fatigue, headache, fever, muscle or joint pain, shortness of breath) were the most important clinical predictors at admission. Age, overall presence of symptoms, shortness of breath, and hypertension were found to be key predictors for PE using our extreme gradient boosted model. This analysis based on the, until now, largest global dataset for this set of problems can inform hospital prioritisation policy and guide long term clinical research and decision-making for COVID-19 patients globally. Our machine learning model developed from an international cohort can serve to better regulate hospital risk prioritisation of at-risk patients.

    DOI: 10.1038/s41598-024-63212-7

    Open Access

    Scopus

  26. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Battaglini D., Kelly T.L., Griffee M., Fanning J., Premraj L., Whitman G., Porto D.B., Arora R., Thomson D., Pelosi P., White N.M., Bassi G.L., Suen J., Fraser J.F., Robba C., Cho S.M., Al-Dabbous T., Alfoudri H., Shamsah M., Alfroukh K., Bairmani Z.A.A., Khalid K.J., Abukhalaf S.M.A., Hadhoud M.M., Abdrabo M.F., Fathi M., Alhouri H., Shahla D.H., Alhadad Q., Hanan M., Elapavaluru S., Berg A., Horn C., Abdelhalim A.R.M.E., Amer A.E., Elnaggar C.O.R., Hassan A.A., Abdelaziz A., Abdelhalim M., Orabi Y.S.S.A., Alaraji Z.A., Muhaisen M.R., Almasri L., Mustafa D., Hamdan S., Al-Saba'a Y., Dalloul Z., Alkahlout M., Jaber H., Aldabbourosama O., Abdalhadi A.A., Hussein A.A.M., Emad Z.K., Khaled S., Mohamed N., Hassanin E., Hamdi A., Gamal M., Emad A., Ragab A., Azizeldin M.G., Hamza A., Omer A.A.M., Fadl alla A.O.A., Abdallahrs A.A.A., Eltayeb A.A., Alhasan M.k.m.a., Abdelgaum E.H., Ahmed A.M., Abdulbaqi L.A., Mohammedelhassan O.A., Ahmed M.M.M., Ali M.T.E.M., Mayasi Y., Schroll S., Meyer D., Velazco J., Ploskanych L., Fikes W., Bagewadi R., Dao M., White H., Laviena A.B., Ehlers A., Shalabi-McGuire M., Witt T., Grazioli L., Lorini L., Grandin E.W., Nunez J., Reyes T., O'Briain D., Hunter S., Ramanan M., Affleck J., Veerendra H.H., Rai S., Russell-Brown J., Nourse M., Joseph M.

    Heart and Lung   68 巻   頁: 131 - 144   2024年11月

     詳細を見る

    出版者・発行元:Heart and Lung  

    Purpose: We aimed to compare the incidence of stroke in low-and middle-income countries (LMICs) versus high-income countries (HICs) in critically ill patients with COVID-19 and its impact on in-hospital mortality. Methods: International observational study conducted in 43 countries. Stroke and mortality incidence rates and rate ratios (IRR) were calculated per admitted days using Poisson regression. Inverse probability weighting (IPW) was used to address the HICs vs. LMICs imbalance for confounders. Results: 23,738 patients [20,511(86.4 %) HICs vs. 3,227(13.6 %) LMICs] were included. The incidence stroke/1000 admitted-days was 35.7 (95 %CI = 28.4–44.9) LMICs and 17.6 (95 %CI = 15.8–19.7) HICs; ischemic 9.47 (95 %CI = 6.57–13.7) LMICs, 1.97 (95 %CI = 1.53, 2.55) HICs; hemorrhagic, 7.18 (95 %CI = 4.73–10.9) LMICs, and 2.52 (95 %CI = 2.00–3.16) HICs; unspecified stroke type 11.6 (95 %CI = 7.75–17.3) LMICs, 8.99 (95 %CI = 7.70–10.5) HICs. In regression with IPW, LMICs vs. HICs had IRR = 1.78 (95 %CI = 1.31–2.42, p < 0.001). Patients from LMICs were more likely to die than those from HICs [43.6% vs 29.2 %; Relative Risk (RR) = 2.59 (95 %CI = 2.29–2.93), p < 0.001)]. Patients with stroke were more likely to die than those without stroke [RR = 1.43 (95 %CI = 1.19–1.72), p < 0.001)]. Conclusions: Stroke incidence was low in HICs and LMICs although the stroke risk was higher in LMICs. Both LMIC status and stroke increased the risk of death. Improving early diagnosis of stroke and redistribution of healthcare resources should be a priority. Trial registration: ACTRN12620000421932 registered on 30/03/2020.

    DOI: 10.1016/j.hrtlng.2024.06.015

    Scopus

  27. 機械的補助循環装置を要する心原性ショックにおける血液プロファイルと出血合併症の検討

    風間 信吾, 春日井 大介, 橋本 祐介, 西田 樹生, 是永 真甫, 守田 裕啓, 大脇 貴之, 酒井 喜規, 本田 純太, 新垣 大智, 田中 卓, 東 倫子, 平岩 宏章, 近藤 徹, 森本 竜太, 奥村 貴裕, 山本 尚範, 沼口 敦, 室原 豊明

    日本集中治療医学会雑誌   31 巻 ( Suppl.1 ) 頁: S688 - S688   2024年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  28. Clinical implications of septic cardiomyopathy: A narrative review 国際誌 Open Access

    Hiraiwa, H; Kasugai, D; Okumura, T; Murohara, T

    MEDICINE   103 巻 ( 17 ) 頁: e37940   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Medicine United States  

    Sepsis is caused by the body's dysregulated response to infection, which can lead to multiorgan injury and death. Patients with sepsis may develop acute cardiac dysfunction, termed septic cardiomyopathy, which is a global but reversible dysfunction of both sides of the heart. This narrative review discusses the mechanistic changes in the heart during septic cardiomyopathy, its diagnosis, existing treatment options regarding severity and course, and emerging treatment approaches. Although no standardized definition for septic cardiomyopathy exists, it is described as a reversible myocardial dysfunction that typically resolves within 7 to 10 days. Septic cardiomyopathy is often diagnosed based on electrocardiography, cardiac magnetic resonance imaging, biomarkers, and direct invasive and noninvasive measures of cardiac output. Presently, the treatment of septic cardiomyopathy is similar to that of sepsis, primarily focusing on acute interventions. Treatments for cardiomyopathy often include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics. However, because of profound hypotension in sepsis, many cardiomyopathy treatments are contraindicated in patients with septic cardiomyopathy. Substantial efforts have been made to study the pathophysiological mechanisms and diagnostic options; however, the lack of a uniform definition for septic cardiomyopathy is challenging for physicians when considering treatments. Another challenge for physicians is that the treatment for septic cardiomyopathy has only focused on acute intervention, whereas the treatment for other cardiomyopathies has been provided on a long-term basis. A better understanding of the underlying mechanisms of septic cardiomyopathy may contribute to the development of a unified definition of the condition and novel treatment options.

    DOI: 10.1097/MD.0000000000037940

    Open Access

    Web of Science

    Scopus

    PubMed

  29. Association between loss of hypercoagulable phenotype, clinical features and complement pathway consumption in COVID-19 国際誌 Open Access

    Kasugai, D; Tanaka, T; Suzuki, T; Ito, Y; Nishida, K; Ozaki, M; Kutsuna, T; Yokoyama, T; Kaneko, H; Ogata, R; Matsui, R; Goshima, T; Hamada, H; Ishii, A; Kodama, Y; Jingushi, N; Ishikura, K; Kamidani, R; Tada, M; Okada, H; Yamamoto, T; Goto, Y

    FRONTIERS IN IMMUNOLOGY   15 巻   頁: 1337070 - 1337070   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Frontiers in Immunology  

    Background: Coronavirus disease 2019 (COVID-19) features a hypercoagulable state, but therapeutic anticoagulation effectiveness varies with disease severity. We aimed to evaluate the dynamics of the coagulation profile and its association with COVID-19 severity, outcomes, and biomarker trajectories. Methods: This multicenter, prospective, observational study included patients with COVID-19 requiring respiratory support. Rotational thromboelastometry findings were evaluated for coagulation and fibrinolysis status. Hypercoagulable status was defined as supranormal range of maximum clot elasticity in an external pathway. Longitudinal laboratory parameters were collected to characterize the coagulation phenotype. Results: Of 166 patients, 90 (54%) were severely ill at inclusion (invasive mechanical ventilation, 84; extracorporeal membrane oxygenation, 6). Higher maximum elasticity (P=0.02) and lower maximum lysis in the external pathway (P=0.03) were observed in severely ill patients compared with the corresponding values in patients on non-invasive oxygen supplementation. Hypercoagulability components correlated with platelet and fibrinogen levels. Hypercoagulable phenotype was associated with favorable outcomes in severely ill patients, while normocoagulable phenotype was not (median time to recovery, 15 days vs. 27 days, P=0.002), but no significant association was observed in moderately ill patients. In patients with severe COVID-19, lower initial C3, minimum C3, CH50, and greater changes in CH50 were associated with the normocoagulable phenotype. Changes in complement components correlated with dynamics of coagulation markers, hematocrit, and alveolar injury markers. Conclusions: While hypercoagulable states become more evident with increasing severity of respiratory disease in patients with COVID-19, normocoagulable phenotype is associated with triggered by alternative pathway activation and poor outcomes.

    DOI: 10.3389/fimmu.2024.1337070

    Open Access

    Web of Science

    Scopus

    PubMed

  30. Effects of acute phase intensive electrical muscle stimulation in COVID-19 patients requireing invasive mechanical ventilation: an observational case-control study. 招待有り 査読有り Open Access

    Scientific Reports     2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41598-024-55969-8

    Open Access

  31. Effects of acute phase intensive electrical muscle stimulation in COVID-19 patients requiring invasive mechanical ventilation: an observational case-control study

    Tsuchikawa, Y; Tanaka, S; Kasugai, D; Nakagawa, R; Shimizu, M; Inoue, T; Nagaya, M; Nasu, T; Omote, N; Higashi, M; Yamamoto, T; Jingushi, N; Numaguchi, A; Nishida, Y

    SCIENTIFIC REPORTS   14 巻 ( 1 ) 頁: 5254   2024年3月

     詳細を見る

    記述言語:英語   出版者・発行元:Scientific Reports  

    We investigated the effects of acute-phase intensive electrical muscle stimulation (EMS) on physical function in COVID-19 patients with respiratory failure requiring invasive mechanical ventilation (IMV) in the intensive care unit (ICU). Consecutive COVID-19 patients requiring IMV admitted to a university hospital ICU between January and April 2022 (EMS therapy group) or between March and September 2021 (age-matched historical control group) were included in this retrospective observational case–control study. EMS was applied to both upper and lower limb muscles for up to 2 weeks in the EMS therapy group. The study population consisted of 16 patients undergoing EMS therapy and 16 age-matched historical controls (median age, 71 years; 81.2% male). The mean period until initiation of EMS therapy after ICU admission was 3.2 ± 1.4 days. The EMS therapy group completed a mean of 6.2 ± 3.7 EMS sessions, and no adverse events occurred. There were no significant differences between the two groups in Medical Research Council sum score (51 vs. 53 points, respectively; P = 0.439) or ICU mobility scale at ICU discharge. Addition of upper and lower limb muscle EMS therapy to an early rehabilitation program did not result in improved physical function at ICU discharge in severe COVID-19 patients.

    DOI: 10.1038/s41598-024-55969-8

    Web of Science

    Scopus

    PubMed

  32. Variability of oxygen requirements in critically ill COVID-19 patients. 招待有り 査読有り 国際共著

    Huth SF, Rothkopf A, Smith L, White N, Bassi GL, Suen JY, Fraser JF; COVID-19 Critical Care Consortium.

    J Glob Health.     2024年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  33. 日本版敗血症診療ガイドライン2024

    志馬 伸朗, 中田 孝明, 矢田部 智昭, 山川 一馬, 青木 善孝, 井上 茂亮, 射場 敏明, 小倉 裕司, 河合 佑亮, 川口 敦, 川崎 達也, 近藤 豊, 櫻谷 正明, 對東 俊介, 土井 研人, 橋本 英樹, 原 嘉孝, 福田 龍将, 松嶋 麻子, 江木 盛時, 久志本 成樹, 大網 毅彦, 菊谷 知也, 相川 玄, 青木 誠, 赤塚 正幸, 淺井 英樹, 阿部 智一, 雨宮 優, 石澤 嶺, 石原 唯史, 石丸 忠賢, 糸洲 佑介, 井上 拓保, 今長谷 尚史, 井村 春樹, 岩崎 直也, 生塩 典敬, 内田 雅俊, 内 倫子, 梅垣 岳志, 梅村 穣, 遠藤 彰, 大井 真里奈, 大内 玲, 大沢 樹輝, 大島 良康, 太田 浩平, 大野 孝則, 岡田 遥平, 岡野 弘, 小川 新史, 柏浦 正広, 春日井 大介, 狩野 謙一, 上谷 遼, 河内 章, 川上 定俊, 川上 大裕, 川村 雄介, 神鳥 研二, 岸原 悠貴, 木村 翔, 久保 健児, 栗原 知己, 小網 博之, 小谷 祐樹, 木庭 茂, 佐藤 威仁, 佐藤 蓮, 澤田 悠輔, 志田 瑶, 島田 忠長, 志水 元洋, 清水 一茂, 白石 拓人, 新貝 達, 丹保 亜希仁, 杉浦 岳, 杉本 健輔, 杉本 裕史, 壽原 朋宏, 関野 元裕, 其田 健司, 對東 真帆子, 高橋 希, 竹下 淳, 武田 親宗, 立野 淳子, 田中 愛子, 谷 昌憲, 谷河 篤, 陳 昊, 土田 拓見, 堤 悠介, 恒光 健史, 出口 亮, 鉄原 健一, 寺山 毅郎, 戸上 由貴, 十時 崇彰, 友田 吉則, 中尾 俊一郎, 長澤 宏樹, 中谷 安寿, 中西 信人, 西岡 典宏, 錦見 満暁, 野口 智子, 野浪 豪, 野村 理, 橋本 克彦, 畠山 淳司, 濵井 康貴, 彦根 麻由, 久宗 遼, 廣瀬 智也, 福家 良太, 藤井 遼, 藤江 直輝, 藤永 潤, 藤浪 好寿, 藤原 翔, 舩越 拓, 本間 康一郎, 牧野 佑斗, 松浦 裕司, 松岡 綾華, 松岡 義, 松村 洋輔, 水野 彰人, 宮本 颯真, 三好 ゆかり, 村田 慧, 村田 哲平, 薬師寺 泰匡, 安尾 俊祐, 山田 浩平, 山田 博之, 山元 良, 山本 良平, 湯本 哲也, 吉田 裕治, 吉廣 尚大, 吉村 聡志, 吉村 旬平, 米倉 寛, 若林 侑起, 和田 剛志, 渡辺 伸一, 井尻 篤宏, 宇賀田 圭, 宇田 周司, 小野寺 隆太, 高橋 正樹, 中島 聡志, 本多 純太, 松本 承大, 日本版敗血症診療ガイドライン2024特別委員会

    日本集中治療医学会雑誌   advpub 巻 ( 0 )   2024年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本集中治療医学会  

    <p>日本集中治療医学会と日本救急医学会は合同で特別委員会を結成し、日本版敗血症診療ガイドライン2024年版(J-SSCG2024)として公表する。今回の改訂により、2012年の初版から数えて3回目の改訂となる。本ガイドラインの目的は、敗血症および敗血症性ショックの診療において、医療従事者が適切な判断を下し、患者の転帰改善につなげるための支援を行うことである。敗血症を認識し初期対応する医師、引き継いで専門家として診療する医師、そして看護師、理学療法士、臨床工学技士、薬剤師など、多職種の医療従事者にとって理解しやすく、使いやすいものを目指した。 J-SSCG2024は、敗血症の診断と感染源のコントロール、抗菌薬治療、初期蘇生・循環作動薬、急性血液浄化、DIC 診断と治療、その他の補助療法、PICS 対策、家族ケア、小児の9領域をカバーし、合計78 個の重要臨床課題を設定した。ガイドラインパネルには両学会から委員21名を任用し、ワーキンググループメンバー107名(医師、看護師、理学療法士、臨床工学技士、薬剤師)のサポートのもとに作成した。将来への発展性を見据えて、多くの若手医療従事者や研究者を含めた。また前回と同様に、中立的立場で領域を横断的に俯瞰するアカデミックガイドライン推進班を構成し、質の担保と作業過程の透明化を目的にパブリックコメントを募集した。作成手法にはGRADE(The Grading of Recommendations Assessment, Development and Evaluation)システムを採用し、質の高いガイドラインを目指した。7個のGood practice statement(GPS)と42個のGRADE に基づく推奨を提示した。その他に、Background question(BQ)22個、future research question(FRQ)12個の解説文を付記した。さらにガイドラインの幅広い普及と教育効果の向上を目指し、スマートフォンアプリを開発した。 本ガイドラインは日本集中治療医学会と日本救急医学会の両機関誌のガイドライン増刊号として同時掲載される。日本集中治療医学会と日本救急医学会の精鋭の英知が詰まった本ガイドラインが、より多くの関係者に利用され、評価され、1人でも多くの敗血症患者の転帰改善に繫がることを願っている。</p>

    DOI: 10.3918/jsicm.2400001

    CiNii Research

  34. Implementation of Recommendations on the Use of Corticosteroids in Severe COVID-19 招待有り 査読有り Open Access

    Camirand-Lemyre F, Merson L, Tirupakuzhi Vijayaraghavan BK, Burrell AJC, Citarella BW, Domingue MP, Lévesque S, Usuf E, Wils EJ, Ohshimo S, Martin-Loeches I, Sandulescu O, Laake JH, Lamontagne F; ISARIC Clinical Characterisation Group.

    JAMA Netw Open     2023年12月

  35. High versus low positive end-expiratory pressure setting in patients receiving veno-venous extracorporeal membrane oxygenation support for severe acute respiratory distress syndrome: study protocol for the multicentre, randomised ExPress SAVER Trial 査読有り Open Access

    BMJ Open     2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1136/bmjopen-2023-072680

    Open Access

  36. High versus low positive end-expiratory pressure setting in patients receiving veno-venous extracorporeal membrane oxygenation support for severe acute respiratory distress syndrome: study protocol for the multicentre, randomised ExPress SAVER Trial 査読有り 国際誌 Open Access

    Nishikimi, M; Ohshimo, S; Hamaguchi, J; Fujizuka, K; Hagiwara, Y; Anzai, T; Ishii, J; Ogata, Y; Aokage, T; Ikeda, T; Yagi, T; Suzuki, G; Ishikura, K; Katsuta, K; Konno, D; Hattori, N; Nakamura, T; Matsumura, Y; Kasugai, D; Kikuchi, H; Iino, T; Kai, S; Hashimoto, H; Yoshida, T; Igarashi, Y; Ogura, T; Matsumura, K; Shimizu, K; Nakamura, M; Ichiba, S; Takahashi, K; Shime, N

    BMJ OPEN   13 巻 ( 10 ) 頁: e072680   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BMJ Open  

    Introduction While limiting the tidal volume to 6 mL/kg during veno-venous extracorporeal membrane oxygenation (V-V ECMO) to ameliorate lung injury in patients with acute respiratory distress syndrome (ARDS) is widely accepted, the best setting for positive end-expiratory pressure (PEEP) is still controversial. This study is being conducted to investigate whether a higher PEEP setting (15 cmH2O) during V-V ECMO can decrease the duration of ECMO support needed in patients with severe ARDS, as compared with a lower PEEP setting. Methods and analysis The study is an investigator-initiated, multicentre, open-label, two-arm, randomised controlled trial conducted with the participation of 20 intensive care units (ICUs) at academic as well as nonacademic hospitals in Japan. The subjects of the study are patients with severe ARDS who require V-V ECMO support. Eligible patients will be randomised equally to the high PEEP group or low PEEP group. Recruitment to the study will continue until a total of 210 patients with ARDS requiring V-V ECMO support have been randomised. In the high PEEP group, PEEP will be set at 15 cmH2O from the start of V-V ECMO until the trials for liberation from V-V ECMO (or until day 28 after the allocation), while in the low PEEP group, the PEEP will be set at 5 cmH2O. Other treatments will be the same in the two groups. The primary endpoint of the study is the number of ECMO-free days until day 28, defined as the length of time (in days) from successful libration from V-V ECMO to day 28. The secondary endpoints are mortality on day 28, in-hospital mortality on day 60, ventilator-free days during the first 60 days and length of ICU stay. Ethics and dissemination Ethics approval for the trial at all the participating hospitals was obtained on 27 September 2022, by central ethics approval (IRB at Hiroshima University Hospital, C2022-0006). The results of this study will be presented at domestic and international medical congresses, and also published in scientific journals.

    DOI: 10.1136/bmjopen-2023-072680

    Open Access

    Web of Science

    Scopus

    PubMed

  37. Implications of uremic cardiomyopathy for the practicing clinician: an educational review 査読有り 国際誌 Open Access

    Hiraiwa Hiroaki, Kasugai Daisuke, Okumura Takahiro, Murohara Toyoaki

    HEART FAILURE REVIEWS   28 巻 ( 5 ) 頁: 1129 - 1139   2023年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Heart Failure Reviews  

    Studies over recent years have redeveloped our understanding of uremic cardiomyopathy, defined as left ventricular hypertrophy, congestive heart failure, and associated cardiac hypertrophy plus other abnormalities that result from chronic kidney disease and are often the cause of death in affected patients. Definitions of uremic cardiomyopathy have conflicted and overlapped over the decades, complicating the body of published evidence, and making comparison difficult. New and continuing research into potential risk factors, including uremic toxins, anemia, hypervolemia, oxidative stress, inflammation, and insulin resistance, indicates the increasing interest in illuminating the pathways that lead to UC and thereby identifying potential targets for intervention. Indeed, our developing understanding of the mechanisms of UC has opened new frontiers in research, promising novel approaches to diagnosis, prognosis, treatment, and management. This educational review highlights advances in the field of uremic cardiomyopathy and how they may become applicable in practice by clinicians. Pathways to optimal treatment with current modalities (with hemodialysis and angiotensin-converting enzyme inhibitors) will be described, along with proposed steps to be taken in research to allow evidence-based integration of developing investigational therapies.

    DOI: 10.1007/s10741-023-10318-1

    Open Access

    Web of Science

    Scopus

    PubMed

  38. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry 招待有り 査読有り

    Griffee MJ, Bozza PT, Reyes LF, Eddington DP, Rosenberger D, Merson L, Citarella BW, Fanning JP, Alexander PMA, Fraser J, Dalton H, Cho SM; ISARIC Clinical Characterisation Group.

    Research and Practice in Thrombosis and Haemostasis     2023年6月

  39. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19 招待有り 査読有り Open Access

    Wainstein M, Spyrison N, Dai D, Ghadimi M, Chávez-Iñiguez JS, Rizo-Topete L, Citarella BW, Merson L, Pole JD, Claure-Del Granado R, Johnson DW, Shrapnel S; ISARIC Characterization Group.

    Kidney Int Rep     2023年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.ekir.2023.05.015

    Open Access

  40. Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19 招待有り 査読有り 国際共著

    Int J Epidemiol     2023年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  41. Neurological manifestations of COVID-19 in adults and children 査読有り 国際共著 Open Access

    Cho SM, White N, Premraj L, Battaglini D, Fanning J, Suen J, Bassi GL, Fraser J, Robba C, Griffee M, Singh B, Citarella BW, Merson L, Solomon T, Thomson D; ISARIC Clinical Characterisation Group.

    Brain     2023年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/brain/awac332

  42. 重症患者の免疫・血栓学的プロファイルの異質性に着目した持続的腎代替療法の回路早期閉塞発生メカニズムの探索

    加藤 孝昭, 沖 尚弥, 春日井 大介, 古橋 和拡

    日本透析医学会雑誌   56 巻 ( 6 ) 頁: 251 - 252   2023年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本透析医学会  

    DOI: 10.4009/jsdt.56.251

    CiNii Research

  43. The Accuracy and Potential Racial and Ethnic Biases of GPT-4 in the Diagnosis and Triage of Health Conditions: Evaluation Study 査読有り 国際共著 国際誌 Open Access

    Ito, N; Kadomatsu, S; Fujisawa, M; Fukaguchi, K; Ishizawa, R; Kanda, N; Kasugai, D; Nakajima, M; Goto, T; Tsugawa, Y

    JMIR MEDICAL EDUCATION   9 巻 ( 1 ) 頁: e47532   2023年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JMIR Medical Education  

    Background: Whether GPT-4, the conversational artificial intelligence, can accurately diagnose and triage health conditions and whether it presents racial and ethnic biases in its decisions remain unclear. Objective: We aim to assess the accuracy of GPT-4 in the diagnosis and triage of health conditions and whether its performance varies by patient race and ethnicity. Methods: We compared the performance of GPT-4 and physicians, using 45 typical clinical vignettes, each with a correct diagnosis and triage level, in February and March 2023. For each of the 45 clinical vignettes, GPT-4 and 3 board-certified physicians provided the most likely primary diagnosis and triage level (emergency, nonemergency, or self-care). Independent reviewers evaluated the diagnoses as "correct" or "incorrect." Physician diagnosis was defined as the consensus of the 3 physicians. We evaluated whether the performance of GPT-4 varies by patient race and ethnicity, by adding the information on patient race and ethnicity to the clinical vignettes. Results: The accuracy of diagnosis was comparable between GPT-4 and physicians (the percentage of correct diagnosis was 97.8% (44/45; 95% CI 88.2%-99.9%) for GPT-4 and 91.1% (41/45; 95% CI 78.8%-97.5%) for physicians; P=.38). GPT-4 provided appropriate reasoning for 97.8% (44/45) of the vignettes. The appropriateness of triage was comparable between GPT-4 and physicians (GPT-4: 30/45, 66.7%; 95% CI 51.0%-80.0%; physicians: 30/45, 66.7%; 95% CI 51.0%-80.0%; P=.99). The performance of GPT-4 in diagnosing health conditions did not vary among different races and ethnicities (Black, White, Asian, and Hispanic), with an accuracy of 100% (95% CI 78.2%-100%). P values, compared to the GPT-4 output without incorporating race and ethnicity information, were all.99. The accuracy of triage was not significantly different even if patients' race and ethnicity information was added. The accuracy of triage was 62.2% (95% CI 46.5%-76.2%; P=.50) for Black patients; 66.7% (95% CI 51.0%-80.0%; P=.99) for White patients; 66.7% (95% CI 51.0%-80.0%; P=.99) for Asian patients, and 62.2% (95%CI 46.5%-76.2%; P=.69) for Hispanic patients. P values were calculated by comparing the outputs with and without conditioning on race and ethnicity. Conclusions: GPT-4's ability to diagnose and triage typical clinical vignettes was comparable to that of board-certified physicians. The performance of GPT-4 did not vary by patient race and ethnicity. These findings should be informative for health systems looking to introduce conversational artificial intelligence to improve the efficiency of patient diagnosis and triage.

    DOI: 10.2196/47532

    Open Access

    Web of Science

    Scopus

    PubMed

  44. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis 査読有り 国際共著 国際誌 Open Access

    Li Bassi G., Gibbons K., Suen J.Y., Dalton H.J., White N., Corley A., Shrapnel S., Hinton S., Forsyth S., Laffey J.G., Fan E., Fanning J.P., Panigada M., Bartlett R., Brodie D., Burrell A., Chiumello D., Elhazmi A., Esperatti M., Grasselli G., Hodgson C., Ichiba S., Luna C., Marwali E., Merson L., Murthy S., Nichol A., Ogino M., Pelosi P., Torres A., Ng P.Y., Fraser J.F., Al-Dabbous T., Alfoudri H., Shamsah M., Elapavaluru S., Berg A., Horn C., Mayasi Y., Schroll S., Meyer D., Velazco J., Ploskanych L., Fikes W., Bagewadi R., Dao M., White H., Meyer D., Ehlers A., Shalabi-McGuire M., Witt T., Grazioli L., Lorini L., Grandin E.W., Nunez J., Reyes T., OBriain D., Hunter S., Ramanan M., Affleck J., Veerendra H.H., Rai S., Russell-Brown J., Nourse M., Joseph M., Mitchell B., Tenzer M., Abe R., Cho H.J., Jeong I.S., Rahman N., Kakar V., Brozzi N., Mehkri O., Krishnan S., Duggal A., Houltham S., Graf J., Diaz R., Orrego R., Delgado C., González J., Sanchez M.S., Piagnerelli M., Sarrazin J.V., Zabert A./.G., Espinosa L., Delgado P., Delgado V., Rincón D.F.B., Yanten A.M.M., Duque M.B., Brodie D., Al-Hudaib A., Callahan M., Taufik M.A., Wardoyo E.Y., Gunawan M., Trisnaningrum N.S.

    Critical Care   26 巻 ( 1 )   2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Critical Care  

    Background: The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis. Methods: We analyzed a convenience sample of patients with COVID-19 and moderate-to-severe ARDS, admitted to 244 intensive care units within the COVID-19 Critical Care Consortium, from February 1, 2020, through October 31, 2021. Patients undergoing at least 2 days and up to 3 consecutive days of NMBAs (NMBA treatment), within 48 h from commencement of IMV were compared with subjects who did not receive NMBAs or only upon commencement of IMV (control). The primary objective in the PS-matched cohort was comparison between groups in 90-day in-hospital mortality, assessed through Cox proportional hazard modeling. Secondary objectives were comparisons in the numbers of ventilator-free days (VFD) between day 1 and day 28 and between day 1 and 90 through competing risk regression. Results: Data from 1953 patients were included. After propensity score matching, 210 cases from each group were well matched. In the PS-matched cohort, mean (± SD) age was 60.3 ± 13.2 years and 296 (70.5%) were male and the most common comorbidities were hypertension (56.9%), obesity (41.1%), and diabetes (30.0%). The unadjusted hazard ratio (HR) for death at 90 days in the NMBA treatment vs control group was 1.12 (95% CI 0.79, 1.59, p = 0.534). After adjustment for smoking habit and critical therapeutic covariates, the HR was 1.07 (95% CI 0.72, 1.61, p = 0.729). At 28 days, VFD were 16 (IQR 0–25) and 25 (IQR 7–26) in the NMBA treatment and control groups, respectively (sub-hazard ratio 0.82, 95% CI 0.67, 1.00, p = 0.055). At 90 days, VFD were 77 (IQR 0–87) and 87 (IQR 0–88) (sub-hazard ratio 0.86 (95% CI 0.69, 1.07; p = 0.177). Conclusions: In patients with COVID-19 and moderate-to-severe ARDS, short course of NMBA treatment, applied early, did not significantly improve 90-day mortality and VFD. In the absence of definitive data from clinical trials, NMBAs should be indicated cautiously in this setting.

    DOI: 10.1186/s13054-022-03983-5

    Open Access

    Scopus

  45. 敗血症性ショックの治療~Beyond the Guidelines~ 難治性敗血症性ショックにおける心原性ショックのマネジメント from Big Data to Bedside

    春日井 大介, 後藤 縁, 平岩 宏章, 沼口 敦, 松田 直之

    日本集中治療医学会雑誌   29 巻 ( Suppl.1 ) 頁: 379 - 379   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  46. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19 査読有り 国際共著 国際誌 Open Access

    Garcia-Gallo E., Merson L., Kennon K., Kelly S., Citarella B.W., Fryer D.V., Shrapnel S., Lee J., Duque S., Fuentes Y.V., Balan V., Smith S., Wei J., Gonçalves B.P., Russell C.D., Sigfrid L., Dagens A., Olliaro P.L., Baruch J., Kartsonaki C., Dunning J., Rojek A., Rashan A., Beane A., Murthy S., Reyes L.F., Abbas A., Abdukahil S.A., Abdulkadir N.N., Abe R., Abel L., Absil L., Jabal K.A., Zayyad H.A., Acharya S., Acker A., Adachi S., Adam E., Adriano E., Adrião D., Ageel S.A., Ahmed S., Aiello M., Ainscough K., Airlangga E., Aisa T., Hssain A.A., Tamlihat Y.A., Akimoto T., Akmal E., Qasim E.A., Al-Dabbous T., Al-Fares A., Alalqam R., Alberti A., Alegesan S., Alegre C., Alessi M., Alex B., Alexandre K., Alfoudri H., Ali A., Ali I., Shah N.A., Sheikh N.A., Alidjnou K.E., Aliudin J., Alkhafajee Q., Allavena C., Allou N., Altaf A., Alves J., Alves J.M., Alves R., Amaral M., Amira N., Ammerlaan H., Ampaw P., Andini R., Andrejak C., Angheben A., Angoulvant F., Ansart S., Anthonidass S., Antonelli M., Antunes de Brito C.A., Anwar K.R., Apriyana A., Arabi Y., Aragao I., Arancibia F., Araujo C., Arcadipane A., Archambault P., Arenz L., Arlet J.B., Arnold-Day C., Aroca A., Arora L., Arora R.

    Scientific Data   9 巻 ( 1 )   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Scientific Data  

    The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 dataset is one of the largest international databases of prospectively collected clinical data on people hospitalized with COVID-19. This dataset was compiled during the COVID-19 pandemic by a network of hospitals that collect data using the ISARIC-World Health Organization Clinical Characterization Protocol and data tools. The database includes data from more than 705,000 patients, collected in more than 60 countries and 1,500 centres worldwide. Patient data are available from acute hospital admissions with COVID-19 and outpatient follow-ups. The data include signs and symptoms, pre-existing comorbidities, vital signs, chronic and acute treatments, complications, dates of hospitalization and discharge, mortality, viral strains, vaccination status, and other data. Here, we present the dataset characteristics, explain its architecture and how to gain access, and provide tools to facilitate its use.

    DOI: 10.1038/s41597-022-01534-9

    Open Access

    Scopus

  47. ARDS clinical practice guideline 2021 査読有り 国際誌 Open Access

    Tasaka S., Ohshimo S., Takeuchi M., Yasuda H., Ichikado K., Tsushima K., Egi M., Hashimoto S., Shime N., Saito O., Matsumoto S., Nango E., Okada Y., Hayashi K., Sakuraya M., Nakajima M., Okamori S., Miura S., Fukuda T., Ishihara T., Kamo T., Yatabe T., Norisue Y., Aoki Y., Iizuka Y., Kondo Y., Narita C., Kawakami D., Okano H., Takeshita J., Anan K., Okazaki S.R., Taito S., Hayashi T., Mayumi T., Terayama T., Kubota Y., Abe Y., Iwasaki Y., Kishihara Y., Kataoka J., Nishimura T., Yonekura H., Ando K., Yoshida T., Masuyama T., Sanui M., Nakashima T., Masunaga A., Tanaka A., Inoue A., Higashi A., Tanikawa A., Ujiro A., Takayama C., Kasugai D., Ueno D., Satoh D., Kai S., Ota K., Hagiwara Y., Hamaguchi J., Fujii R., Hongo T., Masunaga N., Yamamoto R., Uchimido R., Terayama T., Hokari S., Sakamoto H., Dongli , Nakataki E., Tabata E., Okazawa S., Kotajima F., Ishimaru G., Hoshino H., Yoshida H., Iwai H., Nakagawa H., Sugimura H., Narumiya H., Nakamura H., Sugimoto H., Hashimoto H., Ito H., Dote H., Imahase H., Sato H., Katsurada M., Osawa I., Kamei J., Maki J., Sugihara J., Fujimoto J., Ishikawa J., Kosaka J., Shibata J., Hashimoto K., Nakano Y.

    Respiratory Investigation   60 巻 ( 4 ) 頁: 446 - 495   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Respiratory Investigation  

    Background: The joint committee of the Japanese Society of Intensive Care Medicine/Japanese Respiratory Society/Japanese Society of Respiratory Care Medicine on ARDS Clinical Practice Guideline has created and released the ARDS Clinical Practice Guideline 2021. Methods: The 2016 edition of the Clinical Practice Guideline covered clinical questions (CQs) that targeted only adults, but the present guideline includes 15 CQs for children in addition to 46 CQs for adults. As with the previous edition, we used a systematic review method with the Grading of Recommendations Assessment Development and Evaluation (GRADE) system as well as a degree of recommendation determination method. We also conducted systematic reviews that used meta-analyses of diagnostic accuracy and network meta-analyses as a new method. Results: Recommendations for adult patients with ARDS are described: we suggest against using serum C-reactive protein and procalcitonin levels to identify bacterial pneumonia as the underlying disease (GRADE 2D); we recommend limiting tidal volume to 4–8 mL/kg for mechanical ventilation (GRADE 1D); we recommend against managements targeting an excessively low SpO2 (PaO2) (GRADE 2D); we suggest against using transpulmonary pressure as a routine basis in positive end-expiratory pressure settings (GRADE 2B); we suggest implementing extracorporeal membrane oxygenation for those with severe ARDS (GRADE 2B); we suggest against using high-dose steroids (GRADE 2C); and we recommend using low-dose steroids (GRADE 1B). The recommendations for pediatric patients with ARDS are as follows: we suggest against using non-invasive respiratory support (non-invasive positive pressure ventilation/high-flow nasal cannula oxygen therapy) (GRADE 2D); we suggest placing pediatric patients with moderate ARDS in the prone position (GRADE 2D); we suggest against routinely implementing NO inhalation therapy (GRADE 2C); and we suggest against implementing daily sedation interruption for pediatric patients with respiratory failure (GRADE 2D). Conclusions: This article is a translated summary of the full version of the ARDS Clinical Practice Guideline 2021 published in Japanese (URL: https://www.jrs.or.jp/publication/jrs_guidelines/). The original text, which was written for Japanese healthcare professionals, may include different perspectives from healthcare professionals of other countries.

    DOI: 10.1016/j.resinv.2022.05.003

    Open Access

    Scopus

  48. The Contribution of Chest X-Ray to Predict Extubation Failure in Mechanically Ventilated Patients Using Machine Learning-Based Algorithms. 査読有り 国際誌 Open Access

    Fukuchi K, Osawa I, Satake S, Ito H, Shibata J, Dohi E, Kasugai D, Miyamoto Y, Ohbe H, Tamoto M, Yamada N, Yoshikawa K, Goto T

    Critical care explorations   4 巻 ( 6 ) 頁: e0718   2022年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/CCE.0000000000000718

    Open Access

    PubMed

  49. Abnormal magnesium levels and their impact on death and acute kidney injury in critically ill children 査読有り 国際誌

    Morooka Hikaru, Tanaka Akihito, Kasugai Daisuke, Ozaki Masayuki, Numaguchi Atsushi, Maruyama Shoichi

    PEDIATRIC NEPHROLOGY   37 巻 ( 5 ) 頁: 1157 - 1165   2022年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Pediatric Nephrology  

    Background: The prevalence of magnesium imbalance in critically ill children is very high. However, its significance in the development of acute kidney injury (AKI) and mortality remains unknown. Methods: In this retrospective observational study from 2010 to 2018, the pediatric-specific intensive care database was analyzed. We included critically ill children aged > 3 months and those without chronic kidney disease. Patients were diagnosed with AKI, according to the Kidney Disease Improving Global Outcomes (KDIGO) study. We calculated the initial corrected magnesium levels (cMg) within 24 h and used a spline regression model to evaluate the cut-off values for cMg. We analyzed 28-day mortality and its association with AKI. The interaction between AKI and magnesium imbalance was evaluated. Results: The study included 3,669 children, of whom 105 died within 28 days, while 1,823 were diagnosed with AKI. The cut-off values for cMg were 0.72 and 0.94 mmol/L. Both hypermagnesemia and hypomagnesemia were associated with 28-day mortality (odds ratio [OR] = 2.99, 95% confidence interval [CI] = 1.89–4.71, p < 0.001; OR = 2.80, 95% CI = 1.60–4.89, p < 0.001). Hypermagnesemia was associated with AKI (OR = 1.52, 95% CI = 1.27–1.82, p < 0.001), while neither hypermagnesemia nor hypomagnesemia interacted with the AKI stage on the 28-day mortality. Conclusions: Abnormal magnesium levels were associated with 28-day mortality in critically ill children. AKI and hypermagnesemia had a strong association. Graphical abstract: “A higher resolution version of the Graphical abstract is available as Supplementary information”. [Figure not available: see fulltext.]

    DOI: 10.1007/s00467-021-05331-1

    Web of Science

    Scopus

    PubMed

  50. Recurrence of Overdose Suicide Attempt index: a novel scoring system for predicting the recurrence of intentional overdose Open Access

    Hirose Masayuki, Kasugai Daisuke, Tajima Kousuke, Takahashi Hiroshi, Yamada Shigeki, Hirakawa Akihiko

    NAGOYA JOURNAL OF MEDICAL SCIENCE   84 巻 ( 2 ) 頁: 301 - 310   2022年5月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nagoya Journal of Medical Science  

    Repeated suicide attempts through intentional overdose are not infrequent, but little is known about the risk factors associated with intentional overdose. We investigated these risk factors within 1 year of discharge from hospital and developed an index predicting recurrence. This retrospective observational study included 419 patients admitted to our hospital between 2011 and 2018 due to intentional overdose. Of these, 43 (10.0%) repeated an overdose within 1 year of discharge. The risk factors with the highest odds ratios from multivariate logistic regression analyses were used to develop an index assessing Recurrence of Overdose Suicide Attempt. The following variables were significantly associated with recurrence and were included in the index: anxiety and/or insomnia at discharge; use of five or more psychotropic medications; diagnosis of an ICD-F4 anxiety disorders; and female sex (odds ratios: 4.24; 5.52; 2.41; and 3.41, respectively). The area under the receiver operating characteristic curve of the index was 0.797. Sensitivity, specificity, and positive and negative predictive values for Recurrence of Overdose Suicide Attempt >4 points (out of 6) were 72.1%, 75.8%, 25.4%, and 96.0%, respectively. Our novel index predicted the recurrence of intentional overdose with a good negative predictive value and may therefore be a useful screening tool for this high-risk population.

    DOI: 10.18999/nagjms.84.2.301

    Open Access

    Web of Science

    Scopus

  51. Bedside cannulation for veno-venous extracorporeal membrane oxygenation using portable X-ray system in a coronavirus disease patient. 査読有り

    Kondo T, Kuwayama T, Hiraiwa H, Kasugai D, Goto Y, Numaguchi A, Katsu T, Matsui T, Hashimoto N, Tanaka A, Morimoto R, Okumura T, Murohara T

    Journal of cardiology cases   25 巻 ( 3 ) 頁: 185 - 187   2022年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of Cardiology Cases  

    Transportation of patients with coronavirus disease (COVID)-19 outside isolation rooms should be avoided to prevent further spread of the disease. Here, we report a safe and accurate bedside cannulation method for veno-venous extracorporeal membrane oxygenation (VV-ECMO) in a COVID-19 patient in the intensive care unit. A 71-year-old man was admitted to our hospital and diagnosed as having COVID-19 pneumonia. We decided to initiate VV-ECMO therapy because maintaining blood oxygen saturation was difficult despite the mechanical ventilation. We placed two flat-panel detectors behind the patient's chest and the right inguinal area. We repeatedly imaged and monitored insertion of wires and cannulas using a portable X-ray system. Cannulas were successfully inserted in the appropriate position, and VV-ECMO was initiated without any complications. <Learning objective: Transportation of patients with coronavirus disease outside isolation rooms carries the risk of further spread of the disease. By repeatedly acquiring images using a portable X-ray system, safe and accurate cannulation for veno-venous extracorporeal membrane oxygenation cannulation can be performed at the bedside in the intensive care unit.>

    DOI: 10.1016/j.jccase.2021.09.008

    Scopus

    PubMed

  52. Effects of evidence-based ICU care on long-term outcomes of patients with sepsis or septic shock (ILOSS): protocol for a multicentre prospective observational cohort study in Japan 査読有り 国際誌 Open Access

    Liu Keibun, Kotani Toru, Nakamura Kensuke, Chihiro Takai, Morita Yasunari, Ishii Kenzo, Fujizuka Kenji, Yasumura Daisetsu, Taniguchi Daisuke, Hamagami Tomohiro, Shimojo Nobutake, Nitta Masakazu, Hongo Takashi, Akieda Kazuki, Atsuo Maeda, Kaneko Tadashi, Sakuda Yutaka, Andoh Kohkichi, Nagatomi Akiyoshi, Tanaka Yukiko, Irie Yuhei, Kamijo Hiroshi, Hanazawa Manabu, Kasugai Daisuke, Ayaka Matsuoka, Oike Kenji, Lefor Alan Kawarai, Takahashi Kunihiko, Katsukawa Hajime, Ogura Takayuki

    BMJ OPEN   12 巻 ( 3 ) 頁: e054478   2022年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BMJ open  

    INTRODUCTION: Sepsis is not only the leading cause of death in the intensive care unit (ICU) but also a major risk factor for physical and cognitive impairment and mental disorders, known as postintensive care syndrome (PICS), reduced health-related quality of life (HRQoL) and even mental health disorders in patient families (PICS-family; PICS-F). The ABCDEF bundle is strongly recommended to overcome them, while the association between implementing the bundle and the long-term outcomes is also unknown. METHODS AND ANALYSIS: This is a multicentre prospective observational study at 26 ICUs. All consecutive patients between 1 November 2020 and 30 April 2022, who are 18 years old or older and expected to stay in an ICU for more than 48 hours due to sepsis or septic shock, are enrolled. Follow-up to evaluate survival and PICS/ PICS-F will be performed at 3, 6 and 12 months and additionally every 6 months up to 5 years after hospital discharge. Primary outcomes include survival at 12 months, which is the primary outcome, and the incidence of PICS defined as the presence of any physical impairment, cognitive impairment or mental disorders. PICS assessment scores, HRQoL and employment status are evaluated. The association between the implementation rate for the ABCDEF bundle and for each of the individual elements and long-term outcomes will be evaluated. The PICS-F, defined as the presence of mental disorders, and HRQoL of the family is also assessed. Additional analyses with data up to 5 years follow-up are planned. ETHICS AND DISSEMINATION: This study received ethics approvals from Saiseikai Utsunomiya Hospital (2020-42) and all other participating institutions and was registered in the University Hospital Medical Information Network Clinical Trials Registry. Informed consent will be obtained from all patients. The findings will be published in peer-reviewed journals and presented at scientific conferences. TRIAL REGISTRATION NUMBER: UMIN000041433.

    DOI: 10.1136/bmjopen-2021-054478

    Open Access

    Web of Science

    Scopus

    PubMed

  53. Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort 査読有り 国際共著 Open Access

    ISARIC Clinical Characterisation Group

    Elife     2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.7554/eLife.70970

    Open Access

  54. The protective effect of tight-fitting powered air-purifying respirators during chest compressions 査読有り Open Access

    Goto Yukari, Jingushi Naruhiro, Hiraiwa Hiroaki, Ogawa Hiroaki, Sakai Yoshinori, Kasugai Daisuke, Tanaka Taku, Higashi Michiko, Yamamoto Takanori, Numaguchi Atsushi

    AMERICAN JOURNAL OF EMERGENCY MEDICINE   49 巻   頁: 172 - 177   2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:American Journal of Emergency Medicine  

    Background: Airborne personal protective equipment is required for healthcare workers when performing aerosol-generating procedures on patients with infectious diseases. Chest compressions, one of the main components of cardiopulmonary resuscitation, require intense and dynamic movements of the upper body. We aimed to investigate the protective effect of tight-fitting powered air-purifying respirators (PAPRs) during chest compressions. Methods: This single-center simulation study was performed from February 2021 to March 2021. The simulated workplace protection factor (SWPF) is the concentration ratio of ambient particles and particles inside the PAPR mask; this value indicates the level of protection provided by a respirator when subjected to a simulated work environment. Participants performed continuous chest compressions three times for 2 min each time, with a 4-min break between each session. We measured the SWPF of the tight-fitting PAPR during chest compression in real-time mode. The primary outcome was the ratio of any failure of protection (SWPF <500) during the chest compression sessions. Results: Fifty-four participants completed the simulation. Overall, 78% (n = 42) of the participants failed (the measured SWPF value was less than 500) at least one of the three sessions of chest compressions. The median value and interquartile range of the SWPF was 4304 (685–16,191). There were no reports of slipping down of the respirator or mechanical failure during chest compressions. Conclusions: Although the median SWPF value was high during chest compressions, the tight-fitting PAPR did not provide adequate protection.

    DOI: 10.1016/j.ajem.2021.06.012

    Open Access

    Web of Science

    Scopus

    PubMed

  55. The value of open-source clinical science in pandemic response: lessons from ISARIC 査読有り 国際共著 Open Access

    The ISARIC Clinical Characterisation Group

    Lancet Infect Dis.     2021年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/S1473-3099(21)00565-X

    Open Access

  56. 尿中抗原陰性・喀痰PCR陽性のレジオネラ肺炎との混合感染であったCOVID-19の一症例

    後藤 縁, 小川 広晃, 春日井 大介, 田中 卓, 平岩 宏章, 東 倫子, 山本 尚範, 神宮司 成弘, 沼口 敦, 松田 直之

    日本集中治療医学会雑誌   28 巻 ( Suppl.2 ) 頁: 384 - 384   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  57. Assessment of Critical Care Surge Capacity During the COVID-19 Pandemic in Japan 査読有り 国際共著 国際誌 Open Access

    Yamamoto Takanori, Ozaki Masayuki, Kasugai Daisuke, Burnham Gilbert

    HEALTH SECURITY   19 巻 ( 5 ) 頁: 479 - 487   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Health Security  

    Japan has the highest proportion of older adults worldwide but has fewer critical care beds than most high-income countries. Although the COVID-19 infection rate in Japan is low compared with Europe and the United States, by the end of 2020, several infected people died in ambulances because they could not find hospitals to accept them. Our study aimed to examine the Japanese healthcare system's capacity to accommodate critically ill COVID-19 patients during the pandemic. We created a model to estimate bed and staff capacity at 3 levels of pandemic response (conventional, contingency, and crisis), as defined by the US National Academy of Medicine, and the function of Japan's healthcare system at each level. We then compared our estimates of the number of COVID-19 patients requiring intensive care at peak times with the national health system capacity using expert panel data. Our findings suggest that Japan's healthcare system currently can accommodate only a limited number of critically ill COVID-19 patients. It could accommodate the surge of pandemic demands by converting nonintensive care unit beds to critical care beds and using nonintensive care unit staff for critical care. However, bed and staff capacity should not be expanded uniformly, so that the limited number of physicians and nurses are allocated efficiently and so staffing does not become the bottleneck of the expansion. Training and deploying physicians and nurses to provide immediate intensive care is essential. The key is to introduce and implement the concept and mechanism of tiered staffing in the Japanese healthcare system. More importantly, most intensive care facilities in Japanese hospitals are small-scaled and thinly distributed in each region. The government needs to introduce an efficient system for smooth dispatching of medical personnel among hospitals regardless of their founding institutions.

    DOI: 10.1089/hs.2020.0227

    Open Access

    Web of Science

    Scopus

    PubMed

  58. COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study 査読有り 国際共著 Open Access

    ISARIC Clinical Characterisation Group

    Infection     2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s15010-021-01599-5

    Open Access

  59. An appraisal of respiratory system compliance in mechanically ventilated covid-19 patients 査読有り 国際共著 Open Access

    Li Bassi G, Suen JY, Dalton HJ, White N, Shrapnel S, Fanning JP, Liquet B, Hinton S, Vuorinen A, Booth G, Millar JE, Forsyth S, Panigada M, Laffey J, Brodie D, Fan E, Torres A, Chiumello D, Corley A, Elhazmi A, Hodgson C, Ichiba S, Luna C, Murthy S, Nichol A, Ng PY, Ogino M, Pesenti A, Trieu HT, Fraser JF; COVID-19 Critical Care Consortium.

    critical care     2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s13054-021-03518-4

    Open Access

  60. Usefulness of Respiratory Mechanics and Laboratory Parameter Trends as Markers of Early Treatment Success in Mechanically Ventilated Severe Coronavirus Disease: A Single-Center Pilot Study 査読有り 国際誌 Open Access

    Kasugai Daisuke, Ozaki Masayuki, Nishida Kazuki, Hiraiwa Hiroaki, Jingushi Naruhiro, Numaguchi Atsushi, Omote Norihito, Shindo Yuichiro, Goto Yukari

    JOURNAL OF CLINICAL MEDICINE   10 巻 ( 11 )   2021年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:Journal of Clinical Medicine  

    Whether a patient with severe coronavirus disease (COVID-19) will be successfully liberated from mechanical ventilation (MV) early is important in the COVID-19 pandemic. This study aimed to characterize the time course of parameters and outcomes of severe COVID-19 in relation to the timing of liberation from MV. This retrospective, single-center, observational study was performed using data from mechanically ventilated COVID-19 patients admitted to the ICU between 1 March 2020 and 15 December 2020. Early liberation from ventilation (EL group) was defined as successful extubation within 10 days of MV. The trends of respiratory mechanics and laboratory data were visualized and compared between the EL and prolonged MV (PMV) groups using smoothing spline and linear mixed effect models. Of 52 admitted patients, 31 mechanically ventilated COVID-19 patients were included (EL group, 20 (69%); PMV group, 11 (31%)). The patients’ median age was 71 years. While in-hospital mortality was low (6%), activities of daily living (ADL) at the time of hospital discharge were significantly impaired in the PMV group compared to the EL group (mean Barthel index (range): 30 (7.5–95) versus 2.5 (0–22.5), p = 0.048). The trends in respiratory compliance were different between patients in the EL and PMV groups. An increasing trend in the ventilatory ratio during MV until approximately 2 weeks was observed in both groups. The interaction between daily change and earlier liberation was significant in the trajectory of the thrombin–antithrombin complex, antithrombin 3, fibrinogen, C-reactive protein, lymphocyte, and positive end-expiratory pressure (PEEP) values. The indicator of physiological dead space increases during MV. The trajectory of markers of the hypercoagulation status, inflammation, and PEEP were significantly different depending on the timing of liberation from MV. These findings may provide insight into the pathophysiology of COVID-19 during treatment in the critical care setting.

    DOI: 10.3390/jcm10112513

    Open Access

    Web of Science

    Scopus

    PubMed

  61. Failure of non-invasive respiratory support after 6 hours from initiation is associated with ICU mortality 査読有り 国際誌 Open Access

    Nishikimi Mitsuaki, Nishida Kazuki, Shindo Yuichiro, Shoaib Muhammad, Kasugai Daisuke, Yasuda Yuma, Higashi Michiko, Numaguchi Atsushi, Yamamoto Takanori, Matsui Shigeyuki, Matsuda Naoyuki

    PLOS ONE   16 巻 ( 4 ) 頁: e0251030   2021年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PLoS ONE  

    A previous study has shown that late failure (> 48 hours) of high-flow nasal cannula (HFNC) was associated with intensive care unit (ICU) mortality. The aim of this study was to investigate whether failure of non-invasive respiratory support, including HFNC and non-invasive positive pressure ventilation (NPPV), was also associated with the risk of mortality even if it occurs in the earlier phase. We retrospectively analyzed 59 intubated patients for acute respiratory failure due to lung diseases between April 2014 and June 2018. We divided the patients into 2 groups according to the time from starting non-invasive ventilatory support until their intubation: ≤6 hours failure and > 6 hours failure group. We evaluated the differences in the ICU mortality between these two groups. The multivariate logistic regression analysis showed the highest mortality in the > 6 hours failure group as compared to the ≤6 hours failure group, with a statistically significant difference (p < 0.01). It was also associated with a statistically significant increased 30-day mortality and decreased ventilator weaning rate. The ICU mortality in patients with acute respiratory failure caused by lung diseases was increased if the time until failure of HFNC and NPPV was more than 6 hours.

    DOI: 10.1371/journal.pone.0251030

    Open Access

    Web of Science

    Scopus

    PubMed

  62. A case of reexpansion pulmonary edema and acute pulmonary thromboembolism associated with diffuse large B-cell lymphoma treated with venovenous extracorporeal membrane oxygenation. 査読有り

    Kazama S, Hiraiwa H, Kimura Y, Ozaki R, Shibata N, Arao Y, Oishi H, Kato H, Kuwayama T, Yamaguchi S, Kondo T, Furusawa K, Morimoto R, Okumura T, Bando YK, Sato T, Shimada K, Kiyoi H, Nakamura G, Yasuda Y, Kasugai D, Ogawa H, Higashi M, Yamamoto T, Jingushi N, Ozaki M, Numaguchi A, Goto Y, Matsuda N, Murohara T

    Journal of cardiology cases   23 巻 ( 1 ) 頁: 53 - 56   2021年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of Cardiology Cases  

    A 37-year-old man diagnosed with diffuse large B-cell lymphoma two weeks previously, visited our emergency department with sudden dyspnea. He had a severe respiratory failure with saturated percutaneous oxygen at 80% (room air). Chest radiography showed a large amount of left pleural effusion. After 1000 mL of the effusion was urgently drained, reexpansion pulmonary edema (RPE) occurred. Despite ventilator management, oxygenation did not improve and venovenous extracorporeal membrane oxygenation (VV-ECMO) was initiated in the intensive care unit. The next day, contrast-enhanced computed tomography showed a massive thrombus in the right pulmonary artery, at this point the presence of pulmonary thromboembolism (PTE) was revealed. Fortunately, the patient's condition gradually improved with anticoagulant therapy and VV-ECMO support. VV-ECMO was successfully discontinued on day 4, and chemotherapy was initiated on day 8. We speculated the following mechanism in this case: blood flow to the right lung significantly reduced due to acute massive PTE, and blood flow to the left lung correspondingly increased, which could have caused RPE in the left lung. Therefore, our observations suggest that drainage of pleural effusion when contralateral blood flow is impaired due to acute PTE may increase the risk of RPE. <Learning objective: This is a case of reexpansion pulmonary edema (RPE) in the left lung following acute pulmonary thromboembolism (PTE) in the right lung associated with malignant lymphoma, managed by venovenous extracorporeal membrane oxygenation. Contralateral pleural drainage could increase the risk of RPE because contralateral pulmonary blood flow is assumed to increase when PTE obstructs blood flow. Pleural drainage should be performed carefully in patients with malignant tumors because PTE may be hidden.>

    DOI: 10.1016/j.jccase.2020.08.013

    Scopus

    PubMed

  63. Relative bradycardia as a clinical feature in patients with coronavirus disease 2019 (COVID-19): A report of two cases. 査読有り 国際誌

    Hiraiwa H, Goto Y, Nakamura G, Yasuda Y, Sakai Y, Kasugai D, Jinno S, Tanaka T, Ogawa H, Higashi M, Yamamoto T, Jingushi N, Ozaki M, Numaguchi A, Kondo T, Morimoto R, Okumura T, Matsuda N, Murohara T

    Journal of cardiology cases   22 巻 ( 6 ) 頁: 260 - 264   2020年12月

     詳細を見る

    記述言語:英語   出版者・発行元:Journal of Cardiology Cases  

    We treated two patients with COVID-19 pneumonia requiring mechanical ventilation. Case 1 was a 73-year-old Japanese man. Computed tomography (CT) revealed ground-glass opacities in both lungs. He had severe respiratory failure with a partial pressure of oxygen in arterial blood/fraction of inspiratory oxygen ratio (P/F ratio) of 203. Electrocardiogram showed a heart rate (HR) of 56 beats/min, slight ST depression in leads II, III, and aVF, and mild saddle-back type ST elevation in leads V1 and V2. High-sensitivity cardiac troponin T (cTnT) level was slightly elevated. Despite a high fever and hypoxemia, his HR remained within 50–70 beats/min. Case 2 was a 52-year-old Japanese woman. CT revealed ground-glass opacities in the lower left lung. Electrocardiogram showed a HR of only 81 beats/min, despite a body temperature of 39.2 °C, slight ST depression in leads V4, V5, V6, and a prominent U wave in multiple leads. She had an elevated cTnT and a P/F ratio of 165. Despite a high fever and hypoxemia, her HR remained within 50–70 beats/min. Both patients had a poor compensatory increase in their HR, despite their critical status. Relative bradycardia could be a cardiovascular complication and is an important clinical finding in patients with COVID-19. <Learning objective: We report two Japanese cases of COVID-19 pneumonia with relative bradycardia as a condition and no significant compensatory increase in heart rate despite high fever and severe hypoxemia. Relative bradycardia in COVID-19 might be associated with myocardial injury due to not only direct viral involvement but also systemic inflammation. We should carefully observe the occurrence of relative bradycardia because it could potentially be a clinical sign of COVID-19.>

    DOI: 10.1016/j.jccase.2020.07.015

    Scopus

    PubMed

  64. Maximum Norepinephrine Dosage Within 24 Hours as an Indicator of Refractory Septic Shock: A Retrospective Study 査読有り 国際誌

    Kasugai Daisuke, Hirakawa Akihiko, Ozaki Masuyuki, Nishida Kazuki, Ikeda Takao, Takahashi Kunihiko, Matsui Shigeyuki, Uenishi Norimichi

    JOURNAL OF INTENSIVE CARE MEDICINE   35 巻 ( 11 ) 頁: 1285 - 1289   2020年11月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of Intensive Care Medicine  

    Background: The management of refractory septic shock remains a major challenge in critical care and its early indicators are not fully understood. We hypothesized that the maximum norepinephrine dosage within 24 hours of intensive care unit (ICU) admission may be a useful indicator of early mortality in patients with septic shock. Methods: In this retrospective single-center observational study, patients with septic shock admitted to the emergency ICU of an academic medical center between April 2011 and March 2017 were included. Individuals with cardiac arrest and those with do-not-resuscitate orders before admission were excluded. We analyzed if the maximum norepinephrine dosage within 24 hours of ICU admission (MD24) was associated with 7-day mortality. Results: Among 152 patients with septic shock, 20 (15%) did not survive by day 7. The receiver operating characteristic curve analysis for predicting 7-day mortality revealed a cutoff of MD24 of 0.6 μg/kg/min (sensitivity 47%, specificity 93%). In the multivariable regression analysis, a higher MD24 was significantly associated with 7-day mortality (odds ratio: 7.20; 95% confidence interval [CI]: 2.02-25.7; P =.002) but not with 30-day mortality. Using the inverse probability of treatment weighting method in a propensity scoring analysis, a higher MD24 was significantly associated with 7-day (hazard ratio [HR]: 8.9; 95% CI: 3.2-25.0; P <.001) and 30-day mortality (HR: 2.7; 95% CI: 1.2-5.8; P =.012). Conclusions: An MD24 ≥0.6 μg/kg/min was significantly associated with 7-day mortality in patients with septic shock and may therefore be a useful indicator of refractory septic shock.

    DOI: 10.1177/0885066619860736

    Web of Science

    Scopus

    PubMed

  65. Prognostic Impact of Parameters of Metabolic Acidosis in Critically Ill Children with Acute Kidney Injury: A Retrospective Observational Analysis Using the PIC Database 査読有り 国際誌 Open Access

    Morooka Hikaru, Kasugai Daisuke, Tanaka Akihito, Ozaki Masayuki, Numaguchi Atsushi, Maruyama Shoichi

    DIAGNOSTICS   10 巻 ( 11 )   2020年11月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Diagnostics  

    Acute kidney injury (AKI) is a major complication of sepsis that induces acid-base imbalances. While creatinine levels are the only indicator for assessing the prognosis of AKI, prognostic importance of metabolic acidosis is unknown. We conducted a retrospective observational study by analyzing a large China-based pediatric critical care database from 2010 to 2018. Participants were critically ill children with AKI admitted to intensive care units (ICUs). The study included 1505 children admitted to ICUs with AKI, including 827 males and 678 females. The median age at ICU admission was 22 months (interquartile range 7–65). After a median follow-up of 10.87 days, 4.3% (65 patients) died. After adjusting for confounding factors, hyperlactatemia, low pH, and low bicarbonate levels were independently associated with 28-day mortality (respective odds ratio: 3.06, 2.77, 2.09; p values: <0.01, <0.01, <0.01). The infection had no interaction with the three parameters. The AKI stage negatively interacted with bicarbonate and pH but not lactate. The current study shows that among children with AKI, hyperlactatemia, low pH, and hypobicarbonatemia are associated with 28-day mortality.

    DOI: 10.3390/diagnostics10110937

    Open Access

    Web of Science

    Scopus

    PubMed

  66. The prognostic impact of right ventricular dysfunction in patients with septic cardiomyopathy 査読有り 国際誌

    Hiraiwa H., Kasugai D., Okumura T., Kazama S., Kimura Y., Shibata N., Arao Y., Oishi H., Kato H., Kuwayama T., Yamaguchi S., Kondo T., Furusawa K., Morimoto R., Murohara T.

    EUROPEAN HEART JOURNAL   41 巻   頁: 1836 - 1836   2020年11月

     詳細を見る

    記述言語:英語  

    Web of Science

  67. 労働衛生の3管理実践でCOVID-19と戦う

    尾崎 将之, 安田 祐真, 春日井 大介, 酒井 喜規, 平岩 宏章, 小川 広晃, 神宮司 成弘, 山本 尚範, 沼口 敦, 後藤 縁, 松田 直之

    日本救急医学会雑誌   31 巻 ( 11 ) 頁: 1391 - 1391   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

  68. 敗血症性凝固障害における血小板減少率の重要性

    春日井 大介, 尾崎 将之, 後藤 縁

    日本救急医学会雑誌   31 巻 ( 11 ) 頁: 1398 - 1398   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

  69. A群溶連菌感染症による腹腔内膿瘍を形成した毒素性ショック症候群の1例

    小川 広晃, 後藤 縁, 神宮司 成弘, 春日井 大介, 平岩 宏章, 東 倫子, 山本 尚範, 尾崎 将之, 沼口 敦, 松田 直之

    日本集中治療医学会雑誌   27 巻 ( Suppl. ) 頁: 555 - 555   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  70. 集中治療領域における急性肝不全の出血リスク

    春日井 大介, 尾崎 将之, 山本 尚範

    日本集中治療医学会雑誌   27 巻 ( Suppl. ) 頁: 421 - 421   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  71. 脳死肝移植待機中に重篤な出血合併症を呈した急性肝不全昏睡型8例の解析

    神宮司 成弘, 春日井 大介, 平岩 宏章, 小川 広晃, 東 倫子, 山本 尚範, 尾崎 将之, 沼口 敦, 後藤 縁, 松田 直之

    日本集中治療医学会雑誌   27 巻 ( Suppl. ) 頁: 544 - 544   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  72. 明日の敗血症診療を科学する 敗血症の診療と臨床研究における患者層別化の必要性

    春日井 大介, 尾崎 将之, 山本 尚範, 後藤 緑, 東 倫子, 平岩 宏章, 中村 元気, 安田 祐真, 沼口 敦, 松田 直之

    日本集中治療医学会雑誌   27 巻 ( Suppl. ) 頁: 248 - 248   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  73. ノルアドレナリン抵抗性敗血症性ショックにおけるバソプレシン反応性の予測因子の解析

    中村 元気, 春日井 大介, 安田 祐真, 東 倫子, 山本 尚範, 尾崎 将之, 後藤 縁, 沼口 敦, 足立 裕史, 松田 直之

    日本集中治療医学会雑誌   27 巻 ( Suppl. ) 頁: 459 - 459   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  74. TMA(血栓性微小血管症)の診断と治療 血栓性微小血管障害(TMA)の診断と治療に関する工夫

    尾崎 将之, 春日井 大介, 平岩 宏章, 小川 広晃, 東 倫子, 山本 尚範, 神宮司 成弘, 後藤 縁, 沼口 敦, 松田 直之

    日本集中治療医学会雑誌   27 巻 ( Suppl. ) 頁: 271 - 271   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  75. Multiple limb compartment syndrome as a manifestation of capillary leak syndrome secondary to metformin and dipeptidyl peptidase IV inhibitor overdose A case report 査読有り Open Access

    Kasugai Daisuke, Tajima Kosuke, Jingushi Naruhiro, Uenishi Norimichi, Hirakawa Akihiko

    MEDICINE   99 巻 ( 29 ) 頁: e21202   2020年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Medicine  

    RATIONALE: Capillary leak syndrome is a condition that increases systemic capillary permeability and causes characteristic manifestations such as recurrent hypovolemia, systemic edema, and hemoconcentration. Acute limb compartment syndrome is a possible complication of severe capillary leak syndrome. However, timely diagnosis and prompt treatment are challenging because of atypical presentation. PATIENT CONCERNS: An 18-year-old woman with a history of clinical depression was admitted to our intensive care unit (ICU) because of metformin and vildagliptin overdose. She developed marked vasodilatory shock with recurrent severe hypovolemia and disseminated intravascular coagulation. After urgent hemodialysis and plasma exchange, she started to stabilize hemodynamically. However, her limbs became stone-hard with massive edema. Her serum creatinine kinase level increased to an extremely high level. DIAGNOSIS: Extremities were distended, and her skin developed pallor with blistering. Intramuscular pressure in both forearms and lower legs was significantly elevated. INTERVENTIONS: Decompressive fasciotomy was performed. Hemodialysis was continued because of rhabdomyolyses-induced acute kidney injury. OUTCOMES: The patient was finally able to walk by herself at the time of hospital discharge on day 109. LESSONS: The possibility of acute compartment syndrome should be considered in patients with marked capillary leakage, especially after aggressive fluid resuscitation. It is important to be aware of the compartment syndrome in an ICU setting because communication barriers often mask typical symptoms and make diagnosis difficult.

    DOI: 10.1097/MD.0000000000021202

    Open Access

    Web of Science

    Scopus

    PubMed

  76. EFFECT OF SUSTAINED HIGH-EFFICIENCY DAILY DIAFILTRATION USING A MEDIATOR-ADSORBING MEMBRANE ON 28-DAY MORTALITY IN SEPTIC SHOCK PATIENTS

    Hasegawa Daisuke, Nishida Kazuki, Kasugai Daisuke, Kawaji Takahiro, Moriyama Kazuhiro, Nishida Osamu

    SHOCK   53 巻   頁: 31 - 32   2020年6月

     詳細を見る

    記述言語:日本語  

    Web of Science

  77. 不断前進、敗血症診療 敗血症性ショックの重症度による層別化 refractory septic shockを定義する

    春日井 大介, 尾崎 将之, 平川 昭彦, 植西 憲達, 松田 直之

    日本救急医学会雑誌   30 巻 ( 9 ) 頁: 598 - 598   2019年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

  78. 働き方改革-現場救急医の本音 バーンアウトを防ぐ救急医の労務管理

    尾崎 将之, 中村 元気, 安田 祐真, 春日井 大介, 小川 広晃, 東 倫子, 山本 尚範, 沼口 敦, 後藤 縁, 松田 直之

    日本救急医学会雑誌   30 巻 ( 9 ) 頁: 610 - 610   2019年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

  79. マンノース結合レクチン阻害薬は志賀毒素による尿細管障害を軽減する

    尾崎 将之, 春日井 大介, 松田 直之, Stahl Gregory

    補体   56 巻 ( 1 ) 頁: 33 - 33   2019年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本補体学会  

▼全件表示

書籍等出版物 1

  1. ICUグリーンノート

    ( 担当: 分担執筆 ,  範囲: 急性肝不全、消化管障害)

    中外医学社  2021年6月 

     詳細を見る

    記述言語:日本語

MISC 22

  1. COVID-19凝固線溶異常と重症化メカニズム 凝固プロファイルのダイナミクスから微小血栓形成によるCOVID-19の重症化メカニズムに迫る

    春日井 大介, 沓名 健雄, 野田 友則, 横山 俊樹, 尾崎 将之, 濱田 博史, 多田 将士, 五島 隆宏, 山本 尚範, 後藤 縁  

    日本集中治療医学会雑誌29 巻 ( Suppl.1 ) 頁: 310 - 310   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  2. 重症COVID-19患者におけるせん妄の実態とリスク

    後藤 縁, 春日井 大介  

    日本集中治療医学会雑誌29 巻 ( Suppl.1 ) 頁: 496 - 496   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  3. 重症COVID-19 腹臥位療法を中心に COVID-19ARDSにおける腹臥位の効果性に寄与する因子の検討

    田中 卓, 春日井 大介, 桑山 輔, 山本 尚徳, 東 倫子, 神宮司 成弘, 後藤 縁, 沼口 敦  

    日本集中治療医学会雑誌29 巻 ( Suppl.1 ) 頁: 324 - 324   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  4. 血液検査モニタリングデータを用いた体外式膜型人工肺患者の出血イベントリスクの同定

    加藤 孝昭, 近藤 璃菜子, 磯野 知紘, 池ヶ谷 厚, 長谷川 静香, 小山 冨生, 春日井 大介, 田中 卓, 後藤 縁  

    日本集中治療医学会雑誌29 巻 ( Suppl.1 ) 頁: 452 - 452   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  5. 敗血症性ショックの治療~Beyond the Guidelines~ 難治性敗血症性ショックにおける心原性ショックのマネジメント from Big Data to Bedside

    春日井 大介, 後藤 縁, 平岩 宏章, 沼口 敦, 松田 直之  

    日本集中治療医学会雑誌29 巻 ( Suppl.1 ) 頁: 379 - 379   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  6. ICUにおける多数傷病者発生への備え COVID-19パンデミック時の患者急増に対する日本の集中治療受け入れ能力の評価

    山本 尚範, 尾崎 将之, 春日井 大介  

    日本集中治療医学会雑誌29 巻 ( Suppl.1 ) 頁: 340 - 340   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  7. COVID-19凝固線溶異常と重症化メカニズム 重症COVID-19症例における血中補体分子濃度の推移

    尾崎 将之, 春日井 大介, 山本 尚範, 吉田 拓也, 安田 祐真, 中村 元気, 守田 裕啓, 井上 卓也  

    日本集中治療医学会雑誌29 巻 ( Suppl.1 ) 頁: 311 - 311   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  8. 救急医学の飛躍に向けたyoung investigators networkの構築

    春日井 大介  

    日本救急医学会雑誌33 巻 ( 10 ) 頁: 663 - 663   2022年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

  9. 重症COVID-19肺炎における深層学習を用いたCT画像評価と臨床パラメーターの検討

    坂東 皓介, 春日井 大介, 後藤 縁, 小田 昌宏, 森 健策  

    日本救急医学会雑誌33 巻 ( 10 ) 頁: 760 - 760   2022年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

  10. 重症COVID-19感染症における高度徐脈の臨床的意義についての検討

    本多 純太, 春日井 大介, 成田 伸伍, 田中 卓, 東 倫子, 山本 尚範, 神宮寺 成弘, 沼口 敦, 後藤 縁, 松田 直之  

    日本救急医学会雑誌33 巻 ( 10 ) 頁: 761 - 761   2022年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

  11. 新型コロナウィルス感染症重症例において血清C4濃度低下は予後不良を示唆する可能性がある

    尾崎 将之, 春日井 大介, 西田 樹生, 中村 元気, 安田 祐真, 井上 卓也  

    日本救急医学会雑誌33 巻 ( 10 ) 頁: 760 - 760   2022年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

  12. 救急医療と宇宙開発 2070年代における宇宙都市構想に向けて

    水野 光規, 坂東 皓介, 本多 純太, 酒井 喜規, 春日井 大介, 東 倫子, 田中 卓, 神宮司 成弘, 山本 尚範, 後藤 縁, 沼口 敦  

    日本救急医学会雑誌33 巻 ( 10 ) 頁: 870 - 870   2022年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

  13. 新型コロナウィルス感染症重症例における補体タンパクの解析

    尾崎 将之, 春日井 大介, 西田 樹生, 中村 元気, 安田 祐真, 井上 卓也  

    補体59 巻 ( 1 ) 頁: 59 - 59   2022年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本補体学会  

  14. 【みんなで総復習!COVID-19の呼吸管理とケア~急性期から回復期へつなぐNext Step~】(Part.1)COVID-19のキホンをおさえよう COVID-19の病型分類と重症化パターン

    春日井 大介  

    みんなの呼吸器Respica19 巻 ( 6 ) 頁: 709 - 714   2021年12月

  15. 重症COVID-19に対するステロイドパルス療法を用いた治療戦略の解析

    坂東 皓介, 春日井 大介, 田中 卓, 後藤 縁  

    日本救急医学会雑誌32 巻 ( 12 ) 頁: 1579 - 1579   2021年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

  16. 重症COVID-19症例における血中補体分子C3、C4濃度の推移

    尾崎 将之, 春日井 大介, 吉田 拓也, 安田 祐真, 中村 元気, 守田 裕啓, 井上 卓也  

    日本救急医学会雑誌32 巻 ( 12 ) 頁: 1483 - 1483   2021年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本救急医学会  

  17. COVID-19に合併する血栓症・心血管疾患 重症COVID-19における血栓症と抗凝固療法 ROTEMの有用性についての検討

    平岩 宏章, 春日井 大介, 桑山 輔, 田中 卓, 東 倫子, 山本 尚範, 神宮司 成弘, 沼口 敦, 奥村 貴裕, 室原 豊明, 後藤 縁  

    日本動脈硬化学会総会プログラム・抄録集53回 巻   頁: 115 - 115   2021年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本動脈硬化学会  

  18. COVID-19に伴う凝固線溶異常の傾向と対策 重症COVID-19におけるAPTT比を用いた凝固管理の限界とROTEMを併用した抗凝固療法の可能性の探索

    春日井 大介, 平岩 宏章, 田中 卓, 神宮司 成弘, 後藤 縁, 沼口 敦  

    日本集中治療医学会雑誌28 巻 ( Suppl.2 ) 頁: 275 - 275   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  19. 集中治療における下痢対策を極める 集中治療における下痢対策 止下痢薬を中心に

    東 倫子, 春日井 大介, 山本 尚範, 田中 卓, 平岩 宏章, 小川 広晃, 神宮司 成弘, 後藤 縁, 沼口 敦, 松田 直之  

    日本集中治療医学会雑誌28 巻 ( Suppl.2 ) 頁: 281 - 281   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  20. 敗血症性心筋症患者における右心機能と予後の関連

    平岩 宏章, 春日井 大介, 小川 広晃, 東 倫子, 山本 尚範, 神宮司 成弘, 沼口 敦, 後藤 縁, 松田 直之, 室原 豊明  

    日本集中治療医学会雑誌28 巻 ( Suppl.2 ) 頁: 419 - 419   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  21. 救急内科系集中治療領域における病態に応じた循環管理を達成するためのSmart monitoring

    春日井 大介  

    日本集中治療医学会雑誌28 巻 ( Suppl.2 ) 頁: 154 - 154   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本集中治療医学会  

  22. 重症COVID-19症例における血中補体分子濃度の推移

    尾崎 将之, 春日井 大介, 吉田 拓也, 安田 祐真, 中村 元気, 守田 裕啓, 井上 卓也  

    補体58 巻 ( 1 ) 頁: 59 - 59   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本補体学会  

▼全件表示

講演・口頭発表等 6

  1. ゼロから始める多施設共同トランスレーショナルリサーチ:ASCULAPIUS研究の展望 招待有り

    春日井大介

    第50回日本集中治療医学会学術総会  2023年3月3日  日本集中治療医学会

     詳細を見る

    開催年月日: 2023年3月

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    開催地:京都   国名:日本国  

  2. 凝固プロファイルのダイナミクスから 微小血栓形成によるCOVID-19の重症化メカニズムに迫る

    春日井大介

    日本集中治療医学会総会  2022年3月19日 

     詳細を見る

    開催年月日: 2022年3月

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

  3. 難治性敗血症性ショックにおける 心原性ショックのマネジメント :from Big Data to Bedside

    春日井大介, 後藤縁, 平岩宏章, 沼口敦, 松田直之

    日本集中治療医学会総会  2022年3月19日 

     詳細を見る

    開催年月日: 2022年3月

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:web  

  4. 重症 COVID-19 における APTT 比を用いた凝固管理の限界と ROTEM を併用した抗凝固療法の可能性の探索

    春日井大介

    第48回日本集中治療医学会学術集会  2021年2月12日  黒田 泰弘

     詳細を見る

    開催年月日: 2021年2月

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:WEB   国名:日本国  

  5. 持続可能なトランスレーショナル研究基盤構築による診療と研究の両立

    春日井大介

    第51回日本集中治療医学会学術総会  2024年3月14日  日本集中治療医学会

     詳細を見る

    開催年月日: 2024年3月

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:日本  

  6. 救急内科系集中治療領域における病態に応じた循環管理を達成するための Smart monitoring 招待有り

    春日井大介

    第48回日本集中治療医学会学術集会  2021年2月12日  黒田 泰弘

     詳細を見る

    開催年月日: 2021年2月

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    開催地:WEB   国名:日本国  

▼全件表示

共同研究・競争的資金等の研究課題 6

  1. ミッドカインを活用した新型コロナウイルス(COVID-19) 重症化予測簡易判定系の研究・開発

    2022年4月 - 2024年3月

    沖縄県  沖縄イノベーション・エコシステム共同研究推進事業 

      詳細を見る

    担当区分:研究分担者  資金種別:競争的資金

    配分額:15000000円

  2. 重症新型コロナウイルス感染症の多発微小肺血栓塞栓症に対する治療を開発するための臨床試験体制の確立

    2021年4月 - 2022年3月

    日本医療研究開発機構  新興・再興感染症に対する革新的医薬品等開発推進研究事業 

      詳細を見る

    担当区分:研究分担者  資金種別:競争的資金

    配分額:19500000円 ( 直接経費:15000000円 、 間接経費:4500000円 )

  3. 生命の危機に瀕した重症未診断疾患のリアルタイムendotyping法を開発するための基盤構築

    2023年

    医学研究奨励助成事業 

  4. 急性呼吸促拍症候群のモニタリングデータを用いたフェノタイ ピング・エンドタイピング法の開発

    2023年

    研究助成 

  5. 重症新型コロナウイルス(COVID-19)肺炎のモニタリングデータを用いたTemporal Fusion Transformerによる病態悪化の検知法確立

    2021年10月 - 2023年9月

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2000000円

  6. 敗血症性凝固障害の異質性を解決するための病型分類法の確立

    2020年3月 - 2021年2月

    令和元年度(第50回)研究奨励金 

    春日井大介

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:500000円

▼全件表示

科研費 3

  1. ビッグデータと凝固プロファイリングによる敗血症性凝固障害主要メカニズムの解明

    研究課題/研究課題番号:22K09180  2022年4月 - 2025年3月

    科学研究費助成事業  基盤研究(C)

    春日井 大介, 西田 一貴

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    本研究では敗血症性凝固障害発症・重症化のリスク因子の解明及び重症化に寄与する主要メカニズムを明らかにする。国内外の2つの大規模なデータベースを利用して、敗血症性凝固障害の発症・重症化予測因子を明らかにし、機械学習により凝固障害の重症化を予測する精度の高いモデルを構築する。次に、、包括的凝固機能プロファイル測定を活用した主要な凝固障害のフェノタイプ毎のモニタリング方法を探索的に明らかにする。

  2. 一細胞RNA-seqによるARDS異質性の解明

    研究課題/研究課題番号:25K12297  2025年4月 - 2028年3月

    科学研究費助成事業  基盤研究(C)

    京 道人, 春日井 大介

      詳細を見る

    担当区分:研究分担者 

    急性呼吸窮迫症候群(ARDS)は死亡率が約40%にも至る致死的疾患ですが,ARDSに対する特異的な治療法は限られています.
    本研究ではARDSの異質性に着目し、一細胞RNA sequenceという技術を用いて、治療反応や予後が異なるサブタイプのメカニズムを明らかにします。また、その炎症メカニズムの違いに寄与する新規免疫細胞分画の機能を明らかにし、新規治療標的を同定することを目的とします.

  3. 病態に強固な関連がある敗血症新規サブクラス分類の開発

    研究課題/研究課題番号:23K27696  2023年4月 - 2026年3月

    科学研究費助成事業  基盤研究(B)

    工藤 大介, 田宮 元, 早川 峰司, 菱沼 英史, 久志本 成樹, 成田 暁, 山川 一馬, 佐藤 哲哉, 小柴 生造, 湯本 哲也, 後藤 匡啓, 近藤 豊, 石原 唯史, 佐藤 幸男, 錦見 満曉, 堤 悠介, 高山 渉, 鈴木 浩大, 春日井 大介

      詳細を見る

    担当区分:研究分担者 

    【研究デザイン】多施設共同前向き探索的研究【対象患者】18歳以上のSepsis-3診断基準を満たす敗血症患者【研究方法】以下、3工程で行う。
    ①データ収集・解析、①-a. 患者背景データ・診療データの収集、①-b. 遺伝子データ収集およびゲノムワイド関連解析、①-c. 代謝物質データ収集およびメタボローム関連解析。①-d. 脂質データ収集およびリピドーム関連解析。② サブクラス分類およびサブクラスによる治療効果の違いに関する検証。③ サブクラスの推定モデル開発と内的検証。